Sideroblastic Anemia
Sideroblastic anemia is a group of anemias characterized by defective heme synthesis leading to mitochondrial iron accumulation in erythroid precursors, forming pathologic ring sideroblasts in the bone marrow.
Sideroblastic Anemia
Sideroblastic anemia (SA) is a heterogeneous group of anemias characterized by the presence of ring sideroblasts in the bone marrow — these are erythroid precursors (erythroblasts/normoblasts) that have pathological iron-laden mitochondria forming a perinuclear ring (≥ 5 siderotic granules encircling at least one-third of the nucleus on Prussian blue stain). The fundamental problem is defective incorporation of iron into protoporphyrin IX to form heme within mitochondria, leading to mitochondrial iron overload and ineffective erythropoiesis despite adequate or even excessive total body iron stores.
Let's break down the name:
- "Sidero-" = Greek for iron
- "-blast" = immature precursor cell
- So a "sideroblast" is literally an iron-containing immature red cell precursor. The "ring" refers to the ring of iron-loaded mitochondria around the nucleus.
The key conceptual point: the body has plenty of iron, but it cannot use it properly. Iron gets delivered to the mitochondria for heme synthesis, but the final steps (particularly the insertion of iron into protoporphyrin IX by ferrochelatase, or earlier steps in the heme biosynthetic/ALA synthase pathway) are dysfunctional. Iron therefore accumulates in the mitochondria, forming the characteristic ring pattern.
Key Concept
Sideroblastic anemia is NOT iron deficiency. It is a disorder of iron utilization (specifically heme synthesis within mitochondria). Serum iron and ferritin are typically normal or elevated, and TIBC is normal or low — the opposite pattern to iron deficiency anemia.
Ring sideroblasts are defined as erythroblasts with ≥ 5 siderotic (iron-positive) granules encircling ≥ one-third of the nucleus on Prussian blue (Perls') stain of bone marrow aspirate. [1][2]
2. Epidemiology and Risk Factors
- Overall prevalence: Rare as a primary/congenital condition; more commonly encountered as an acquired form (part of the myelodysplastic syndrome spectrum)
- Congenital/hereditary forms: Very rare; X-linked sideroblastic anemia (XLSA) is the most common hereditary form
- X-linked: predominantly affects males (females are carriers, though some manifesting carriers exist due to skewed X-inactivation)
- Typically presents in childhood or adolescence, but can present in adulthood
- Acquired forms:
- Myelodysplastic syndrome with ring sideroblasts (MDS-RS): Most common acquired form. Median age at diagnosis is 65–70 years, with a slight male predominance
- Secondary/reversible causes: depend on the offending agent (drugs, toxins, nutritional deficiency)
| Category | Risk Factors |
|---|---|
| Genetic | ALAS2 gene mutation (X-linked), SLC25A38, mitochondrial DNA mutations, thiamine transporter mutations |
| Nutritional | Pyridoxine (vitamin B6) deficiency, copper deficiency, chronic alcoholism (folate depletion + direct mitochondrial toxicity) |
| Drugs/toxins | Isoniazid (INH), chloramphenicol, cycloserine, linezolid, lead poisoning, zinc excess (causes secondary copper deficiency), ethanol |
| Hematologic | MDS (clonal stem cell disorder), myeloproliferative neoplasms |
| Age | MDS-RS predominantly in elderly (> 60 years) |
- Chronic alcoholism is an important secondary cause; alcohol is directly toxic to mitochondria and also depletes pyridoxine and folate [3]
- Isoniazid (INH) use for tuberculosis treatment — TB remains a significant disease in Hong Kong. INH is a pyridoxine antagonist and a well-recognized cause of sideroblastic anemia. This is why pyridoxine supplementation (10 mg/day) is co-prescribed with INH in HK practice [1]
- Lead exposure — industrial/occupational in certain settings
- MDS-RS in the aging Hong Kong population is probably the most commonly encountered clinical scenario of sideroblastic anemia in adults
High Yield – Hong Kong Relevance
In HK, always think of isoniazid (TB treatment) and chronic alcohol use as reversible causes of sideroblastic anemia. INH inhibits pyridoxal phosphate (the active form of B6), which is a critical cofactor for ALA synthase — the first and rate-limiting enzyme of heme synthesis.
3. Anatomy and Function: Heme Synthesis and Iron Metabolism
To understand sideroblastic anemia, you must understand the heme biosynthetic pathway and normal iron handling in erythroblasts. This is the "first principles" approach.
Heme synthesis occurs partly in the mitochondria and partly in the cytoplasm of erythroid precursors:
Key enzymes and their locations:
| Step | Enzyme | Location | Cofactor/Substrate |
|---|---|---|---|
| 1 (rate-limiting) | ALA synthase 2 (ALAS2) | Mitochondria | Pyridoxal phosphate (B6) |
| 2 | ALA dehydratase | Cytoplasm | Zinc (inhibited by lead) |
| 3-6 | Various | Cytoplasm | — |
| 7 | Coproporphyrinogen oxidase | Mitochondria | — |
| 8 (final) | Ferrochelatase | Mitochondria | Inserts Fe²⁺ into protoporphyrin IX |
- Transferrin carries Fe³⁺ in blood → binds transferrin receptor 1 (TfR1) on erythroblast surface
- The transferrin-TfR1 complex is internalized by receptor-mediated endocytosis
- In the endosome, acidification releases Fe³⁺ → reduced to Fe²⁺ by STEAP3
- Fe²⁺ is exported from endosome via DMT1 into the cytoplasm
- Fe²⁺ is then imported into the mitochondria via mitoferrin-1 (SLC25A37)
- Inside mitochondria, Fe²⁺ is used for:
- Heme synthesis (ferrochelatase inserts Fe²⁺ into protoporphyrin IX)
- Iron-sulfur (Fe-S) cluster biogenesis (important for electron transport chain and other enzymes)
- Excess iron in the cytoplasm is stored as ferritin
When any step in this pathway is disrupted — whether at:
- ALAS2 (enzyme itself mutated, or its B6 cofactor is deficient/antagonized)
- Iron-sulfur cluster assembly (ABCB7 mutations, etc.)
- Mitochondrial function broadly (mitochondrial DNA deletions, toxins like alcohol or lead)
- Ferrochelatase (though isolated ferrochelatase deficiency causes erythropoietic protoporphyria rather than classic SA)
→ Iron continues to be imported into mitochondria but cannot be incorporated into heme → Iron accumulates in mitochondria → Mitochondria become swollen and dysfunctional → On Prussian blue stain, you see the classic perinuclear ring of blue granules = ring sideroblasts
First Principles Understanding
The mitochondrion is the "factory" for the final steps of heme synthesis. If the factory is broken (whether the enzyme ALAS2 is defective, B6 is missing, or the mitochondria themselves are damaged), iron keeps arriving at the factory door via mitoferrin-1 but has nowhere to go. It piles up in the mitochondria, forming iron-laden rings visible on Prussian blue stain.
4. Etiology and Pathophysiology
4.2 Congenital (Hereditary) Sideroblastic Anemias
- Gene: ALAS2 (Xp11.21) — encodes the erythroid-specific form of ALA synthase
- Inheritance: X-linked recessive
- Pathophysiology:
- ALAS2 is the first and rate-limiting enzyme of heme synthesis in erythroid cells
- Mutations reduce enzyme activity → decreased ALA production → decreased heme synthesis
- Iron continues to enter mitochondria but cannot be used → mitochondrial iron accumulation
- Heme also normally provides negative feedback on iron uptake (via IRP/IRE system); decreased heme removes this brake → further iron loading
- Many ALAS2 mutations affect the pyridoxal phosphate (PLP/B6) binding site → these are the pyridoxine-responsive forms (important therapeutically!)
- Clinical: Variable severity; some patients present in infancy with severe anemia, others not until adulthood. Male predominance but female carriers can manifest due to lyonization (skewed X-inactivation)
Some ALAS2 mutations affect the B6 binding site, making them pyridoxine-responsive — always trial pyridoxine in congenital SA. [1]
| Gene | Mechanism |
|---|---|
| SLC25A38 | Encodes mitochondrial glycine transporter; glycine cannot enter mitochondria → ALAS2 cannot make ALA (glycine is a substrate). Second most common hereditary cause. Severe, usually pyridoxine-unresponsive. |
| GLRX5 | Involved in Fe-S cluster assembly; deficiency disrupts IRP1 regulation → represses ALAS2 translation via IRE on ALAS2 mRNA |
| HSPA9 (mortalin) | Mitochondrial chaperone involved in Fe-S cluster assembly |
| ABCB7 | Mitochondrial ABC transporter; exports Fe-S clusters; mutations cause XLSA with ataxia (XLSA/A) — actually X-linked |
- Pearson syndrome: Large-scale mitochondrial DNA deletion → affects multiple mitochondrial enzymes → sideroblastic anemia + exocrine pancreatic insufficiency + lactic acidosis. Usually fatal in infancy.
- MLASA (Myopathy, Lactic Acidosis, Sideroblastic Anemia): PUS1 or YARS2 mutations → impaired mitochondrial protein synthesis
- Thiamine-responsive megaloblastic anemia (TRMA/Rogers syndrome): SLC19A2 mutation → defective thiamine transporter → megaloblastic anemia with ring sideroblasts + sensorineural deafness + diabetes
4.3 Acquired Sideroblastic Anemias
MDS-RS is the most common form of sideroblastic anemia encountered in clinical practice. Per WHO 2022 / ICC classification, it requires ≥ 15% ring sideroblasts in BM erythroblasts (or ≥ 5% if SF3B1 mutation is present). [1][2]
-
Pathophysiology:
- SF3B1 mutation found in ~80-90% of MDS-RS cases — this is the hallmark molecular feature
- SF3B1 encodes a component of the RNA splicing machinery (spliceosome)
- Mutation causes aberrant splicing of multiple genes, including:
- ABCB7 (mitochondrial iron export) → mis-spliced → reduced expression → mitochondrial iron accumulation
- Multiple other targets affecting mitochondrial function
- Results in ineffective erythropoiesis: many erythroblasts die in the marrow before maturing (intramedullary hemolysis)
- Clinically: isolated anemia (often macrocytic) in an elderly patient with ring sideroblasts on BM biopsy
-
Prognosis: MDS-RS (especially with SF3B1 mutation and single-lineage dysplasia) is considered a lower-risk MDS with relatively indolent course and low risk of leukemic transformation (median survival ~6 years with SF3B1 mutation)
-
MDS/MPN-RS-T (MDS/MPN with ring sideroblasts and thrombocytosis): Features of both MDS-RS AND myeloproliferative neoplasm (sustained thrombocytosis ≥ 450 × 10⁹/L). Often has both SF3B1 AND JAK2 V617F mutations.
This is high yield because these are treatable!
| Cause | Mechanism | Key Points |
|---|---|---|
| Isoniazid (INH) | Inhibits pyridoxal phosphase → depletes pyridoxal phosphate (active B6) → ALAS2 cannot function | Most important drug cause in HK (TB treatment). Prevented by co-prescribing pyridoxine 10-25 mg/day [1] |
| Chloramphenicol | Inhibits mitochondrial protein synthesis (mitochondrial ribosome 70S, similar to bacterial ribosomes) | Dose-dependent; reversible on stopping |
| Linezolid | Same mechanism as chloramphenicol — inhibits mitochondrial protein synthesis | Prolonged courses (> 2 weeks) |
| Cycloserine | Pyridoxine antagonist (similar to INH) | Used as second-line anti-TB drug |
| Ethanol/Alcohol | Direct mitochondrial toxin + depletes pyridoxine and folate + inhibits ALA synthase + impairs heme synthesis | Very common; reversible with abstinence + B6/folate supplementation. The sideroblasts from alcohol disappear within days of stopping alcohol [1] |
| Lead poisoning | Inhibits ALA dehydratase (step 2) AND ferrochelatase (step 8) of heme synthesis → double block | Also causes basophilic stippling (inhibited pyrimidine-5'-nucleotidase) |
| Copper deficiency | Copper is needed for ceruloplasmin (ferroxidase activity for iron export) AND for cytochrome c oxidase (mitochondrial electron transport) | Caused by zinc excess (zinc induces metallothionein in enterocytes which binds copper → malabsorption), gastric bypass surgery, excess zinc supplementation |
| Pyridoxine (B6) deficiency | B6 → pyridoxal phosphate → essential cofactor for ALAS2 | Malnutrition, alcoholism, drug-induced |
High Yield – Reversible Causes
Always consider reversible causes of sideroblastic anemia: isoniazid, alcohol, lead, copper deficiency, and B6 deficiency. These are treatable! A careful drug and social history is essential. [1]
Three major consequences:
-
Ineffective erythropoiesis → Anemia
- Erythroblasts loaded with iron-stuffed mitochondria undergo apoptosis in the marrow (intramedullary death)
- Those that survive produce hypochromic, microcytic red cells (in congenital/B6-related forms) or macrocytic cells (in MDS-RS)
- This is similar to the concept in thalassemia — the marrow is trying hard but failing, producing defective cells
-
Iron overload (secondary hemochromatosis)
- Ineffective erythropoiesis leads to suppressed hepcidin (via increased erythroferrone from expanded erythroid precursors) → increased intestinal iron absorption
- Combined with frequent transfusions → progressive iron loading of liver, heart, endocrine organs
- This is the major cause of morbidity and mortality in chronic SA
-
Dimorphic red cell population (in some forms, particularly XLSA)
- A mixture of hypochromic microcytic cells (defective) and normochromic normocytic cells (from relatively normal erythropoiesis)
- Results in a high RDW (red cell distribution width) — this is a useful clue!
5. Classification
| Category | Subcategory | Gene/Mechanism |
|---|---|---|
| Hereditary | X-linked (most common hereditary) | ALAS2 |
| X-linked with ataxia | ABCB7 | |
| Autosomal recessive | SLC25A38, GLRX5, HSPA9 | |
| Mitochondrial | mtDNA deletions (Pearson), PUS1/YARS2 (MLASA) | |
| Thiamine-responsive | SLC19A2 | |
| Acquired – Clonal | MDS-RS (MDS-RS-SLD, MDS-RS-MLD) | SF3B1 (~80-90%) |
| MDS/MPN-RS-T | SF3B1 + JAK2/CALR/MPL | |
| Acquired – Reversible | Drug-induced | INH, chloramphenicol, linezolid, cycloserine |
| Toxin-induced | Alcohol, lead | |
| Nutritional | B6 deficiency, copper deficiency |
This is very useful clinically because when you see the CBP results, MCV guides your thinking:
| MCV | Likely Cause |
|---|---|
| Microcytic (MCV < 80 fL) | Congenital (XLSA, SLC25A38), lead poisoning, pyridoxine deficiency |
| Normocytic (MCV 80-100 fL) | Some drug-induced, copper deficiency |
| Macrocytic (MCV > 100 fL) | MDS-RS (most common), alcohol-related, some drug-induced (chloramphenicol, linezolid) |
The MCV in sideroblastic anemia is variable — it depends on the underlying cause. Hereditary forms tend to be microcytic (because ALAS2 dysfunction = less heme = less hemoglobin = microcytic). MDS-RS is typically macrocytic (because of dysplastic erythropoiesis). Drug/toxin causes can be any MCV. [1][2]
Exam Pearl
A common mistake is assuming all sideroblastic anemias are microcytic. MDS-RS (the most common acquired form) is typically macrocytic. The hereditary forms are usually microcytic. Drug-induced can be any MCV. Always check the clinical context.
6. Clinical Features
| Symptom | Pathophysiological Basis |
|---|---|
| Fatigue, weakness, exercise intolerance | Reduced hemoglobin → decreased O₂ carrying capacity → tissue hypoxia. This is the cardinal symptom of any anemia. |
| Pallor | Reduced hemoglobin concentration → less oxygenated hemoglobin in cutaneous/mucosal capillary beds → pale appearance. Best assessed at conjunctivae, palmar creases, nail beds. |
| Dyspnea on exertion | Compensatory increase in cardiac output and respiratory rate to maintain tissue O₂ delivery; on exertion, demand exceeds supply → breathlessness |
| Palpitations | Compensatory tachycardia to maintain cardiac output in the setting of reduced O₂ carrying capacity |
| Dizziness/lightheadedness | Cerebral hypoperfusion secondary to anemia-related decreased O₂ delivery |
| Symptoms of iron overload (chronic/severe cases): | |
| - Joint pain, arthralgia | Iron deposition in synovium (hemochromatotic arthropathy), particularly MCP joints 2nd and 3rd → "iron fist" |
| - Abdominal pain (RUQ) | Hepatic iron deposition → hepatomegaly, eventually cirrhosis |
| - Loss of libido, erectile dysfunction, amenorrhea | Iron deposition in pituitary (hypogonadotropic hypogonadism) and gonads |
| - Polyuria, polydipsia | Iron deposition in pancreatic beta cells → "bronze diabetes" |
| - Skin darkening | Iron deposition in skin → bronze/slate-grey discoloration |
| - Symptoms of heart failure (dyspnea, orthopnea, edema) | Iron deposition in myocardium → restrictive/dilated cardiomyopathy |
| Symptoms related to underlying cause: | |
| - Neurological symptoms (lead poisoning) | Lead → peripheral neuropathy (wrist drop/foot drop), encephalopathy in children, abdominal colic |
| - Ataxia (XLSA/A — ABCB7 mutation) | Cerebellar/spinocerebellar degeneration due to defective Fe-S cluster export |
| - Deafness + diabetes (TRMA) | Sensorineural hearing loss + diabetes mellitus in thiamine-responsive megaloblastic anemia |
| - Drug history (INH, anti-TB drugs) | Ask about TB treatment — very relevant in HK |
| - Alcohol use history | Chronic alcoholism → direct toxicity + nutritional deficiency |
| Sign | Pathophysiological Basis |
|---|---|
| Pallor (conjunctival, palmar) | Reduced Hb concentration → pallid mucosal and skin color |
| Tachycardia | Compensatory increase in heart rate to maintain cardiac output |
| Flow murmur (ejection systolic murmur, usually best at left sternal edge / pulmonary area) | Decreased blood viscosity from anemia → increased flow velocity through valves → audible turbulence. Does NOT imply structural valve disease |
| Hepatomegaly | Iron deposition in liver (hemochromatosis) OR extramedullary hematopoiesis OR underlying liver disease (alcohol) |
| Splenomegaly | Extramedullary hematopoiesis (in severe chronic anemia, the spleen resumes its fetal hematopoietic role) OR iron deposition |
| Skin hyperpigmentation (bronze/grey) | Iron deposition in dermal macrophages and melanocyte stimulation → "bronze diabetes" appearance. More prominent in transfusion-dependent patients |
| Signs of liver cirrhosis (spider nevi, palmar erythema, jaundice) | Long-standing hepatic iron overload → hepatic fibrosis → cirrhosis |
| Signs of heart failure (elevated JVP, bilateral pedal edema, bibasal crepitations) | Iron-mediated cardiomyopathy |
| Signs of hypogonadism (testicular atrophy, gynaecomastia, loss of secondary sexual characteristics) | Pituitary iron deposition → reduced gonadotropins |
| Signs specific to underlying cause: | |
| - Burton's line (blue-black line on gingival margin) | Lead poisoning: lead sulfide deposits at gum-tooth junction |
| - Wrist drop, foot drop | Lead → motor neuropathy (predominantly extensor muscles) |
| - Koilonychia (spoon-shaped nails) | NOT typical of sideroblastic anemia (this is iron deficiency); but prolonged severe anemia of any cause may produce nail changes |
| - Cerebellar signs (ataxia, dysmetria, nystagmus) | XLSA with ataxia (ABCB7 mutation) → cerebellar degeneration |
| Peripheral blood smear findings (not physical exam, but found on "examination" of blood): | |
| - Dimorphic red cell population | Two populations — hypochromic microcytic + normochromic normocytic. Classic for sideroblastic anemia (particularly XLSA) |
| - Basophilic stippling | Aggregated ribosomes/RNA remnants. Seen in lead poisoning (inhibited pyrimidine-5'-nucleotidase), thalassemia, and SA |
| - Pappenheimer bodies | Iron-containing inclusions in mature RBCs (siderocytes). Non-heme iron visible on Wright stain, confirmed by Prussian blue stain |
A dimorphic blood film (two populations of red cells — hypochromic microcytic + normochromic normocytic) with Pappenheimer bodies is a classic peripheral smear finding of sideroblastic anemia. The high RDW reflects this dimorphism. [1][2]
This is critical for distinguishing SA from iron deficiency anemia (which can also be microcytic/hypochromic):
| Parameter | Sideroblastic Anemia | Iron Deficiency Anemia |
|---|---|---|
| Serum Iron | ↑ or Normal | ↓ |
| Serum Ferritin | ↑ or Normal | ↓ |
| TIBC | Normal or ↓ | ↑ |
| Transferrin Saturation | ↑ or Normal | ↓ |
| Bone Marrow Iron | ↑↑↑ (ring sideroblasts) | Absent |
Critical Distinction
Both iron deficiency anemia and congenital sideroblastic anemia can be microcytic hypochromic — but the iron studies are opposite. In SA, the body is iron-loaded; in IDA, it is iron-depleted. The bone marrow is the gold standard: absent stainable iron in IDA vs. ring sideroblasts in SA.
The differential diagnosis of microcytic anemia includes Iron Deficiency Anemia, Thalassemia, Anemia of Chronic Disease, Sideroblastic Anemia, and Lead poisoning. [1]
| Feature | IDA | Thalassemia trait | ACD | Sideroblastic Anemia |
|---|---|---|---|---|
| MCV | ↓ | ↓↓ (disproportionate to Hb) | ↓ or N | ↓ (hereditary) or ↑ (MDS-RS) |
| Serum Fe | ↓ | N | ↓ | ↑ or N |
| TIBC | ↑ | N | ↓ | N or ↓ |
| Ferritin | ↓ | N or ↑ | ↑ | ↑ or N |
| RDW | ↑ | N | N | ↑↑ (dimorphic) |
| Film | Target cells, pencil cells | Target cells, basophilic stippling | — | Dimorphic, Pappenheimer bodies |
| BM Iron | Absent | Present | Present (in macrophages, not sideroblasts) | Ring sideroblasts |
7. Relevant Connections to Lecture Material
Classification of anemia by MCV: microcytic (< 80 fL) includes iron deficiency, thalassemia, sideroblastic anemia, anemia of chronic disease, and lead poisoning.
Iron studies in sideroblastic anemia: raised serum iron, raised ferritin, normal/low TIBC, raised transferrin saturation — the opposite of iron deficiency.
The approach to diagnosing anemia: (1) Confirm anemia on CBP, (2) Classify by MCV, (3) Reticulocyte count, (4) Peripheral blood smear, (5) Iron studies, (6) Further Ix as indicated.
Ring sideroblasts on bone marrow aspirate (Prussian blue/Perls' stain) is the diagnostic hallmark of sideroblastic anemia.
In the approach to microcytic anemia, iron studies (serum iron, TIBC, ferritin, transferrin saturation) are essential to differentiate between IDA, ACD, thalassemia, and sideroblastic anemia.
Complete Blood Picture (CBP) includes Hb, MCV, MCH, MCHC, RDW, WCC, platelets. MCV and RDW are key starting points in anemia workup. A high RDW with microcytic anemia may suggest IDA or sideroblastic anemia (dimorphic population).
Myelodysplastic syndromes (including MDS-RS) can be associated with splenomegaly due to extramedullary hematopoiesis. MDS/MPN-RS-T specifically features thrombocytosis and may have more prominent splenomegaly.
MDS is a clonal stem cell disorder characterized by dysplasia in one or more myeloid lineages, ineffective hematopoiesis, and risk of transformation to AML. MDS-RS is a subtype defined by ring sideroblasts ≥ 15% (or ≥ 5% with SF3B1 mutation).
Chronic anemia (including sideroblastic anemia) can present with signs of high-output cardiac failure, and should be considered in patients with unexplained chronic anemia who are not iron deficient.
High Yield Summary
Sideroblastic Anemia — Key Points:
-
Definition: Anemia characterized by ring sideroblasts in bone marrow — iron accumulates in mitochondria because heme synthesis is defective.
-
Pathophysiology: Defect in heme biosynthetic pathway (most commonly ALAS2 or its B6 cofactor) → iron enters mitochondria but cannot be used → mitochondrial iron overload + ineffective erythropoiesis.
-
Classification:
- Congenital: XLSA (ALAS2 mutation — most common hereditary), SLC25A38, ABCB7, Pearson syndrome
- Acquired clonal: MDS-RS (SF3B1 mutation in ~80-90%)
- Acquired reversible: INH, alcohol, lead, copper deficiency, B6 deficiency
-
Clinical Features: Anemia symptoms + iron overload signs (hepatomegaly, skin pigmentation, cardiomyopathy, diabetes, hypogonadism). Dimorphic blood film + Pappenheimer bodies.
-
Iron Studies: ↑ serum iron, ↑ ferritin, normal/↓ TIBC, ↑ transferrin saturation — opposite to IDA.
-
MCV: Variable! Microcytic in hereditary forms, macrocytic in MDS-RS, variable in drug-induced.
-
Diagnosis: Bone marrow aspirate with Prussian blue stain showing ≥ 15% ring sideroblasts (or ≥ 5% with SF3B1 mutation for MDS-RS).
-
HK relevance: Think of INH (TB treatment), alcohol, and MDS-RS in elderly.
Active Recall - Sideroblastic Anemia (Definition, Etiology, Pathophysiology, Clinical Features)
[1] Lecture slides: GC 076. Pallor_diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf; Block A - Pallor_ diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf [2] Lecture slides: Block A - Family history of anaemia_ inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf; GC 047. Family history of anaemia.pdf; Block A - Many members of the family have anaemia.pdf [3] Senior notes: Block A - Hematology Interactive Tutorial.pdf [4] Lecture slides: Block A - Hematology Data Interpretation.pdf [5] Lecture slides: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf [6] Lecture slides: GC 086. Splenomegaly.pdf; Block A - Splenomegaly_ common causes of splenomegaly; myeloproliferative diseases.pdf [7] Lecture slides: GC 060. High white cell count.pdf; Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf [8] Lecture slides: GC 036. Coffee ground vomitustarry stool_upper GI bleeding.pdf
Differential Diagnosis of Sideroblastic Anemia
The differential diagnosis of sideroblastic anemia operates on two levels:
- Level 1 — What else could cause this anemia? (i.e., differential of the presenting blood picture — microcytic, macrocytic, or dimorphic anemia with iron-loaded marrow)
- Level 2 — Once ring sideroblasts are confirmed, what is the underlying cause? (i.e., differential within the sideroblastic anemias themselves)
Both levels are clinically important. A patient doesn't walk in saying "I have sideroblastic anemia" — they present with pallor, fatigue, or an incidental finding of anemia on CBP. You must first work through the differential of anemia, then narrow down once you identify the ring sideroblasts.
Level 1: Differential Diagnosis of the Presenting Anemia
The MCV guides the initial differential. Remember from the previous section that SA can be microcytic, normocytic, or macrocytic depending on the cause — so it can masquerade as many things.
Microcytic anemia differential diagnosis: Thalassemia, Iron deficiency, Sideroblastic anemia (think of MDS, but very rare — and frank MDS would be macrocytic), Anemia of chronic disease. [1]
| Differential | Key Distinguishing Features | Why It Differs from SA |
|---|---|---|
| Iron deficiency anemia (IDA) | ↓ Ferritin, ↑ TIBC, ↓ serum Fe, ↓ transferrin saturation. Pencil cells on film. Absent BM iron stores. | SA has the opposite iron studies: ↑ ferritin, ↓ TIBC, ↑ serum Fe. BM iron is abundant (ring sideroblasts). The mechanism is fundamentally different — IDA lacks iron entirely; SA cannot use the iron it has. |
| Thalassemia trait | Target cells, basophilic stippling on film. MCV disproportionately low for degree of anemia. Normal/↑ Fe studies. Hb electrophoresis abnormal (↑ HbA2 in β-thal trait, ↑ HbH in α-thal). | Thalassemia is a globin chain synthesis defect, not a heme synthesis defect. No ring sideroblasts on BM. RDW is typically normal in thalassemia trait (uniform small cells) vs. ↑↑ in SA (dimorphic population). [1][5] |
| Anemia of chronic disease (ACD) | ↓ serum Fe, ↓ TIBC, ↑ ferritin (acute phase reactant). Often normocytic but can be mildly microcytic. | ACD is driven by hepcidin-mediated iron sequestration — iron is trapped in macrophages, not in erythroblast mitochondria. No ring sideroblasts. TIBC is the most useful differentiator between IDA and ACD (↑ in IDA, ↓ in ACD). [1] |
| Lead poisoning | Basophilic stippling, abdominal colic, motor neuropathy (wrist drop), Burton's line. ↑ blood lead, ↑ free erythrocyte protoporphyrin (FEP), ↑ urinary ALA and coproporphyrin. | Lead actually causes sideroblastic anemia (it inhibits ALA dehydratase and ferrochelatase). So this is both a differential AND a cause. The distinguishing point is the clinical context (occupational exposure, pica in children) and blood lead level. |
Exam Trap
TIBC is most useful in distinguishing iron deficiency anaemia from anaemia of chronic illness. [1] — Serum iron is low in both; ferritin can be confounded by concomitant infection (ferritin is an acute phase reactant). In sideroblastic anemia, serum iron is paradoxically normal or high, which immediately steers you away from IDA.
Macrocytic anemia differential diagnosis: Aplastic anemia, Megaloblastic anemia (B12/folate deficiency), MDS, Liver disease, Hypothyroidism, Drugs (e.g. chemotherapy, antiretrovirals). [1]
| Differential | Key Distinguishing Features | Why It Differs from SA |
|---|---|---|
| Megaloblastic anemia (B12 / folate deficiency) | Macroovalocytes + hypersegmented neutrophils on PBS. Pancytopenia. ↑ LDH and unconjugated bilirubin (intramedullary hemolysis). MCV often > 110–120 fL. Low B12 or folate levels. | MDS-RS also has macrocytosis and intramedullary hemolysis, but the PBS shows dysplastic changes (pseudo-Pelger-Huet cells, hypogranular neutrophils) rather than hypersegmented neutrophils. BM shows ring sideroblasts in MDS-RS vs. megaloblastic erythropoiesis in B12/folate deficiency. Always check B12 and folate in suspected MDS to rule out this treatable mimic. [9][10] |
| Aplastic anemia | Pancytopenia resulting from bone marrow hypoplasia or aplasia. [2] Reticulocytopenia. BM is hypocellular with fat replacement. NO dysplasia, NO infiltration, NO ring sideroblasts. | SA (particularly MDS-RS) has a hypercellular marrow with ring sideroblasts and dysplasia — the opposite of aplastic anemia's empty marrow. Both can have macrocytosis and pancytopenia, but the BM appearance is completely different. [2][9] |
| MDS (other subtypes) | Presence of dysplastic cells ≥ 1 myeloid series, ↑ immature cells and blasts. [9] Pseudo-Pelger-Huet cells on PBS. Cytogenetic abnormalities (del(5q), del(7q), -7, +8). | Other MDS subtypes lack ring sideroblasts (or have < 15%, or < 5% without SF3B1 mutation). MDS-RS is specifically defined by ring sideroblasts AND typically has SF3B1 mutation. The distinction matters for prognosis — MDS-RS with SF3B1 mutation has a more favorable prognosis than other MDS subtypes. [7][9] |
| Alcohol-related macrocytosis | Round macrocytes (not oval). Target cells. Often with liver disease stigmata. MCV usually 100–110 fL. Reversible with abstinence. | Alcohol can cause SA (ring sideroblasts that disappear within days of abstinence). But alcohol also causes macrocytosis without ring sideroblasts (via direct membrane effects on RBCs). So alcohol is both a differential and a cause — the BM biopsy distinguishes. |
| Hypothyroidism | ↑ TSH, ↓ free T4. Macrocytic anemia without dysplasia or ring sideroblasts. | Hypothyroidism causes macrocytosis through unclear mechanisms (possibly reduced cell division rate). No ring sideroblasts. Simple TFTs exclude this. |
| Drug-induced macrocytosis | Chemotherapy (methotrexate, hydroxyurea, azathioprine), antiretrovirals (zidovudine). | Drug history clarifies. Chemotherapy vs. pernicious anemia are the only two common causes of MCV > 120 fL. [1] |
Dimorphic anemia: distinct population of both large and small red cells, MCV averages out. [1]
| Differential | Key Distinguishing Features |
|---|---|
| Combined deficiency (e.g. IDA + B12/folate deficiency) | Two populations on film. Iron studies show depletion. Check B12/folate. No ring sideroblasts. |
| Post-transfusion | Donor normocytes mixed with patient's abnormal cells. Clinical history clarifies. |
| Sideroblastic anemia (particularly XLSA) | Dimorphic film is classic for SA — hypochromic microcytic cells (from defective heme synthesis) mixed with normochromic normocytic cells. Pappenheimer bodies. Ring sideroblasts on BM. ↑ RDW. |
| Early IDA on iron replacement | New normocytic reticulocytes mixing with residual microcytic cells. History of recent iron supplementation. |
Once ring sideroblasts are identified on bone marrow Prussian blue stain, the next question is: What is the underlying cause?
Systematic Approach to Differentiating Causes
| Clinical Clue | Points Toward | Reasoning |
|---|---|---|
| Young male, family history, microcytic | XLSA (ALAS2) | X-linked recessive → males. Reduced ALAS2 → less heme → less Hb → microcytic. Some respond to pyridoxine (B6 binding site mutations). |
| Child with pancreatic insufficiency, lactic acidosis | Pearson syndrome | Mitochondrial DNA deletion → multisystem disease. Sideroblastic anemia + exocrine pancreatic insufficiency. Usually fatal in infancy. |
| Child with deafness + diabetes | TRMA (Rogers syndrome) | SLC19A2 mutation → thiamine transporter defect. Thiamine is needed for many mitochondrial enzymes. Responds to high-dose thiamine. |
| Ataxia + sideroblastic anemia in a male | XLSA with ataxia (ABCB7) | ABCB7 exports Fe-S clusters from mitochondria. Defect → Fe-S cluster deficiency in CNS → spinocerebellar degeneration. |
| On anti-TB medication (INH) | Drug-induced (INH) | INH inhibits pyridoxal phosphase → depletes B6 → ALAS2 dysfunction. [1] Very HK-relevant. Prevented by co-prescribing B6. |
| Heavy alcohol use | Alcohol-related | Ethanol is directly toxic to mitochondria + depletes B6 and folate. Ring sideroblasts resolve within days of abstinence. |
| Occupational exposure, abdominal colic, wrist drop | Lead poisoning | Lead inhibits ALA dehydratase AND ferrochelatase → double block in heme synthesis. Also causes basophilic stippling (inhibits pyrimidine-5'-nucleotidase). |
| Post-gastric bypass, zinc supplementation | Copper deficiency | Zinc induces metallothionein in enterocytes → traps copper → copper malabsorption. Copper needed for ceruloplasmin and cytochrome c oxidase. |
| Elderly patient, macrocytic anemia, cytopenias | MDS-RS | Most common acquired form. SF3B1 mutation in ~80-90%. [7][9] BM shows ≥ 15% ring sideroblasts (or ≥ 5% with SF3B1). Dysplastic features. |
| Elderly, MDS-RS features + thrombocytosis | MDS/MPN-RS-T | Overlap syndrome. Often has SF3B1 + JAK2 V617F. Platelet count ≥ 450 × 10⁹/L. |
The top differential whenever seeing a case of sideroblastic anemia is that it may be an indicator/manifestation of underlying myelodysplastic syndrome. [5]
Once you suspect sideroblastic anemia, here is how you differentiate between the causes:
| Investigation | Purpose | Expected Finding |
|---|---|---|
| Drug and social history | Identify reversible causes | INH, alcohol, lead exposure, zinc supplements, diet |
| Pyridoxine (B6) level | Nutritional/drug-induced deficiency | Low in B6 deficiency, INH use |
| Blood lead level | Lead poisoning | Elevated (> 10 µg/dL concerning, > 25 µg/dL diagnostic) |
| Serum copper, ceruloplasmin | Copper deficiency | Both low |
| Serum zinc | Zinc excess causing copper deficiency | Elevated |
| Bone marrow aspirate with Prussian blue stain | Confirm ring sideroblasts, assess dysplasia | ≥ 15% ring sideroblasts. Dysplasia suggests MDS. [5][9] |
| BM cytogenetics (karyotyping/FISH) | MDS subtyping, prognosis | del(5q), del(7q), -7, +8 in MDS. [9] |
| SF3B1 mutation analysis | Confirm MDS-RS | Present in ~80-90% of MDS-RS; allows diagnosis with only ≥ 5% ring sideroblasts. [7][9] |
| ALAS2 gene sequencing | Hereditary XLSA | Pathogenic variant in ALAS2 |
| Mitochondrial DNA analysis | Pearson syndrome | Large-scale mtDNA deletion |
| Trial of pyridoxine | Distinguish pyridoxine-responsive vs. unresponsive | Reticulocyte rise and Hb improvement within 1-3 months suggests pyridoxine-responsive SA |
Important Differential Considerations by Clinical Context
Both can present with anemia + raised LDH + raised unconjugated bilirubin (because both involve premature destruction of red cell precursors). However:
- Hemolytic anemia: ↑ reticulocytes (compensatory), ↓ haptoglobin, positive DAT (if immune-mediated), extravascular (spherocytes, splenomegaly) or intravascular (hemoglobinuria, ↑ free Hb) hemolysis [3][11]
- Sideroblastic anemia (MDS-RS): Inappropriately low reticulocytes for degree of anemia (because the destruction is intramedullary — erythroblasts die in the marrow before becoming reticulocytes). Haptoglobin may be low. DAT negative. Ring sideroblasts on BM. [1]
Intramedullary hemolysis differential diagnosis: Pernicious anemia, Thalassemia major, MDS. [1] — All three destroy erythroid precursors within the marrow, leading to elevated LDH and unconjugated bilirubin with inappropriately low reticulocytes.
Both have elevated ferritin and transferrin saturation, but:
- Hereditary hemochromatosis (HFE mutations): No anemia (hemoglobin is normal or high). No ring sideroblasts. Genotyping positive (C282Y, H63D). Iron deposition in liver, heart, pancreas, joints.
- Sideroblastic anemia: Anemia is present. Ring sideroblasts on BM. Iron overload is secondary to ineffective erythropoiesis + transfusions.
Both cause ineffective erythropoiesis with iron overload, but:
- CDA: Characterized by multinucleated erythroblasts and inter-nuclear chromatin bridging on BM. No ring sideroblasts. Types I, II, III based on morphology and genetics.
- SA: Ring sideroblasts are the hallmark. No multinucleated erythroblasts.
Ringed sideroblasts: RBC with iron deposition in the form of ring around nuclei (abnormal localization of iron in mitochondria around nucleus). [9]
| Feature | MDS-RS | MDS without RS | AML |
|---|---|---|---|
| Ring sideroblasts | ≥ 15% (or ≥ 5% with SF3B1) | < 15% and no SF3B1 | Variable |
| SF3B1 mutation | ~80-90% | Uncommon | Rare |
| Blasts in BM | < 5% (SLD) or < 5% (MLD) | Variable, < 20% | ≥ 20% [10] |
| Prognosis | Relatively favorable | Depends on subtype | Poor |
| Risk of AML transformation | Low (~5-10%) | Higher in higher-risk MDS | Already AML |
| Condition | MCV | Iron Studies | Reticulocytes | BM Findings | Key Differentiator |
|---|---|---|---|---|---|
| Sideroblastic anemia | Variable | ↑ Fe, ↑ ferritin, N/↓ TIBC | Low/inappropriately normal | Ring sideroblasts | Prussian blue stain showing perinuclear iron ring |
| Iron deficiency anemia | ↓ | ↓ Fe, ↓ ferritin, ↑ TIBC | Low | Absent iron stores | Absent stainable iron on BM |
| Thalassemia trait | ↓↓ | Normal | Normal | Normal iron, no RS | Hb electrophoresis, genetic testing |
| Anemia of chronic disease | N or ↓ | ↓ Fe, ↓ TIBC, ↑ ferritin | Low | Iron in macrophages, not RS | Underlying chronic disease, hepcidin-mediated |
| B12/folate deficiency | ↑↑ | Normal | Low | Megaloblastic changes, no RS | Hypersegmented neutrophils, low B12/folate |
| Aplastic anemia | N or ↑ | Normal | Low | Hypocellular, fat replacement [2] | Empty marrow, no dysplasia |
| MDS (non-RS) | ↑ | Variable | Low | Dysplasia, no/few RS | Cytogenetics, < 15% RS, no SF3B1 |
| Hemolytic anemia | N or ↑ | ↑ Fe | ↑ (compensatory) [3][11] | Erythroid hyperplasia | ↑ reticulocytes, ↓ haptoglobin, ± DAT+ |
| Hereditary hemochromatosis | N | ↑↑ Fe, ↑↑ ferritin, ↑↑ TSAT | Normal | Iron overload, no RS | No anemia, HFE genotyping |
| Lead poisoning | ↓ | N or ↑ Fe | Low | Ring sideroblasts (it IS a cause of SA) | ↑ blood lead, basophilic stippling, clinical Hx |
High Yield Summary — Differential Diagnosis
When you see microcytic anemia with raised iron studies → think sideroblastic anemia (not IDA!).
When you see macrocytic anemia in elderly → MDS-RS is a key differential alongside B12/folate deficiency and other MDS subtypes.
The gold standard to distinguish SA from other anemias is bone marrow Prussian blue stain showing ring sideroblasts.
Once ring sideroblasts are confirmed, differentiate by:
Active Recall - Differential Diagnosis of Sideroblastic Anemia
References
[1] Lecture slides: GC 076. Pallor_diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf; Block A - Pallor_ diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf [2] Lecture slides: Block A - Family history of anaemia_ inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf; GC 047. Family history of anaemia.pdf [3] Senior notes: Block A - Hematology Interactive Tutorial.pdf [5] Lecture slides: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf [7] Lecture slides: GC 060. High white cell count.pdf; Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf [9] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Hematological Diseases — MDS section); MBBS Final MB (Pediatrics) (Felix PY Lai).pdf [10] Senior notes: Ryan Ho Haemtology.pdf (MDS and AML sections) [11] Lecture slides: Haematology Introduction to Haematological investigations (CBP, Clotting).pdf (Haemolytic anaemia laboratory features)
Diagnostic Criteria, Algorithm, and Investigations for Sideroblastic Anemia
1. Diagnostic Criteria
Sideroblastic anemia does not have a single "diagnostic criteria checklist" like SLE or rheumatic fever. Instead, diagnosis is established by demonstrating the hallmark morphological finding on bone marrow examination, then determining the underlying cause. Think of it as a two-step process: (1) prove the sideroblastic anemia exists, then (2) figure out why.
The test used to demonstrate sideroblastic anemia is Perl's Prussian Blue Stain. [5]
Ring sideroblasts → the RBC precursors have a ring of iron-laden mitochondria around the nucleus. And since iron is blue, you will see a blue ring around the nucleus. [5]
Definition of a ring sideroblast (WHO 2022 / ICC 2022):
- An erythroblast with ≥ 5 siderotic (iron-positive) granules arranged in a perinuclear ring encircling ≥ one-third of the nuclear circumference on Prussian blue stain of bone marrow aspirate
Why this specific definition? Normal erythroblasts can have a few scattered iron granules (these are called "normal sideroblasts" — up to 30-50% of normal marrow erythroblasts have 1-4 randomly distributed iron granules representing cytoplasmic ferritin). The ring pattern specifically indicates that iron is trapped in mitochondria (which physically surround the nucleus), distinguishing pathological from physiological iron in erythroblasts.
Since MDS-RS is by far the most commonly encountered sideroblastic anemia in clinical practice, its diagnostic criteria deserve special attention.
Percentage of ring sideroblasts: erythroid precursor, ≥ 5 iron granules encircling ≥ 1/3 of nucleus. [12]
WHO 2022 Classification / ICC 2022 — MDS with Ring Sideroblasts (MDS-RS):
| Criterion | Requirement |
|---|---|
| Cytopenia(s) | ≥ 1 persistent cytopenia (defined as Hb < 10 g/dL, ANC < 1.8 × 10⁹/L, or platelets < 100 × 10⁹/L) |
| Dysplasia | Morphological dysplasia in ≥ 1 myeloid lineage (≥ 10% dysplastic cells in that lineage) |
| Ring sideroblasts | ≥ 15% of erythroid precursors on Prussian blue stain — OR ≥ 5% if SF3B1 mutation is present [7][9] |
| Blasts | < 5% blasts in BM, < 2% in peripheral blood (if ≥ 5% blasts → reclassify as MDS with excess blasts) |
| No AML-defining changes | No t(8;21), inv(16), t(15;17), or other AML-defining genetic abnormalities |
| No isolated del(5q) | If isolated del(5q), classify as MDS with isolated del(5q) instead |
Why Does SF3B1 Lower the Ring Sideroblast Threshold?
The SF3B1 mutation is found in ~80-90% of MDS-RS and is highly specific for this entity. Its presence is so strongly associated with ring sideroblasts that even 5% ring sideroblasts are sufficient for diagnosis. This reflects the understanding that SF3B1 mutation is the driver event — it causes the ring sideroblast phenotype by mis-splicing ABCB7 and other mitochondrial genes. Without the mutation, a higher percentage threshold is needed to ensure you're not calling normal variation pathological.
MDS-RS sub-classification:
| Subtype | Additional Criteria |
|---|---|
| MDS-RS with single-lineage dysplasia (MDS-RS-SLD) | Dysplasia in 1 lineage only. More favorable prognosis. |
| MDS-RS with multi-lineage dysplasia (MDS-RS-MLD) | Dysplasia in ≥ 2 lineages. Slightly less favorable. |
MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T):
| Criterion | Requirement |
|---|---|
| Meets criteria for MDS-RS | As above |
| Sustained thrombocytosis | Platelet count ≥ 450 × 10⁹/L |
| Megakaryocyte morphology | Large, lobulated megakaryocytes (MPN-like) |
| Molecular | Often SF3B1 + JAK2 V617F (or CALR/MPL) |
There are no formal "criteria" analogous to MDS-RS; diagnosis rests on:
- Ring sideroblasts on BM (same morphological definition)
- Genetic confirmation: Pathogenic variant in a known gene (ALAS2, SLC25A38, ABCB7, etc.)
- Exclusion of acquired causes (drugs, toxins, nutritional deficiency, MDS)
- Clinical context: Young age, family history (especially X-linked pattern for ALAS2), ± pyridoxine responsiveness
Again, no formal criteria — diagnosis requires:
- Ring sideroblasts on BM
- Identification of an offending cause (drug, toxin, nutritional deficiency)
- Resolution of ring sideroblasts and anemia after removing the cause (this retrospectively confirms the diagnosis)
The diagnostic workup of sideroblastic anemia follows a logical stepwise approach — from detecting anemia, to characterizing it, to confirming ring sideroblasts, to determining the underlying cause.
High Yield — The Algorithm in One Sentence
3. Investigation Modalities — Detailed Interpretation
3.1 First-Line Blood Tests
Classification of anaemia based on laboratory findings: MCV Low (< 80 fL) — Thalassemia, Iron deficiency, Sideroblastic anemia; MCV Normal (80-99 fL) — Anaemia of chronic disease, Anaemia of renal disease, Acute blood loss, Dimorphic anaemia; MCV High ( > 100 fL) — Aplastic anaemia, Chronic liver disease, Chemotherapy, Alcohol usage, Vitamin B12 or folate deficiency, Myelodysplasia. [1]
| Parameter | Finding in SA | Interpretation |
|---|---|---|
| Hemoglobin | ↓ (variable severity, can be 4-10 g/dL) | Degree of anemia depends on cause: MDS-RS often moderate (Hb 8-10); congenital XLSA can be severe |
| MCV | Variable: ↓ in hereditary, ↑ in MDS-RS, any in drug-induced | Reflects the underlying mechanism. Microcytic = less heme per cell (hereditary/B6-related). Macrocytic = dysplastic erythropoiesis (MDS) |
| MCH | Often ↓ (especially hereditary forms) | Less hemoglobin per cell due to impaired heme synthesis |
| MCHC | ↓ or dimorphic | Hypochromic cells from defective heme; normochromic from residual normal erythropoiesis |
| RDW | ↑↑ (often markedly elevated) | Reflects the dimorphic population — a mixture of hypochromic microcytes and normochromic normocytes. This is a very useful clue! RDW is normal in thalassemia trait (uniform small cells) but high in SA and IDA. [1][5] |
| Reticulocyte count | Low or inappropriately normal | Ineffective erythropoiesis — erythroblasts die in the marrow before becoming reticulocytes. Unlike hemolytic anemia where reticulocytes are elevated. [1] |
| WCC | Normal or ↓ (if MDS) | MDS-RS may have neutropenia due to multilineage dysplasia |
| Platelets | Normal, ↓ (MDS), or ↑ (MDS/MPN-RS-T) | Thrombocytosis ≥ 450 × 10⁹/L suggests MDS/MPN-RS-T |
This is the critical differentiator from IDA and ACD. The pattern in sideroblastic anemia is iron overload/maldistribution, not iron deficiency.
| Parameter | SA Pattern | Why |
|---|---|---|
| Serum Iron | ↑ or Normal | Iron is absorbed and delivered normally; it just can't be used in mitochondria. Builds up in plasma. |
| Ferritin | ↑ or Normal | Reflects total body iron stores, which are increased due to: (1) ineffective erythropoiesis → suppressed hepcidin → increased gut absorption; (2) transfusional iron loading. |
| TIBC | Normal or ↓ | Body is not iron-depleted, so does not upregulate transferrin production. TIBC is the most useful test to distinguish IDA (↑ TIBC) from ACD (↓ TIBC). SA has a similar pattern to ACD for TIBC. [1] |
| Transferrin Saturation (TSAT) | ↑ or Normal | Calculated as (Serum Fe / TIBC) × 100. High because serum iron is high and TIBC is not elevated. |
Exam Trap — Don't Confuse with Hemochromatosis
Both sideroblastic anemia and hereditary hemochromatosis have ↑ ferritin, ↑ TSAT, and ↑ serum iron. The key difference: SA has anemia; hemochromatosis does NOT. Hemochromatosis has normal or even elevated hemoglobin. The anemia in SA is the red flag that iron utilization — not just iron excess — is the problem. [12]
| Test | Purpose | Expected in SA |
|---|---|---|
| Serum B12 and folate | Rule out megaloblastic anemia — essential before diagnosing MDS, as B12/folate deficiency is a treatable mimic of macrocytic anemia with pancytopenia [1][9][10] | Normal (unless concurrent deficiency, e.g., alcoholic patients may have low folate) |
| LFT | Liver disease screening (alcoholic liver disease, hemochromatosis-related cirrhosis) | May show deranged LFTs if iron overload or alcohol-related liver disease |
| RFT | Renal disease as cause of anemia | Usually normal unless concurrent CKD |
| LDH, unconjugated bilirubin | Markers of ineffective erythropoiesis / intramedullary hemolysis | ↑ LDH, ↑ unconjugated bilirubin (from premature destruction of erythroblasts in marrow). Intramedullary hemolysis DDx: Pernicious anemia, Thalassemia major, MDS. [1] |
| Haptoglobin | Hemolysis marker | May be ↓ (consumed by free hemoglobin from intramedullary hemolysis) — but less markedly than in peripheral hemolytic anemias |
| Reticulocyte count | Assess marrow compensatory capacity | Low or inappropriately normal despite anemia — this is the hallmark of ineffective erythropoiesis. Contrasts with hemolytic anemia where reticulocytes are ↑. [1][3] |
| TFTs | Rule out hypothyroidism as cause of macrocytosis | Normal |
| Direct antiglobulin test (DAT/Coombs) | Rule out autoimmune hemolytic anemia | Negative in SA. Would be positive in warm AIHA. [3] |
Workup for microcytic anemia: peripheral blood smear, Fe profile (serum Fe, TIBC) + ferritin, Hb pattern, clotting profile. [12]
The PBS in sideroblastic anemia can provide several key clues BEFORE you even do a bone marrow:
| Finding | Description | Significance |
|---|---|---|
| Dimorphic red cell population | Two distinct populations: hypochromic microcytes (pale, small — from defective heme synthesis) + normochromic normocytes (normal — from residual functional erythropoiesis) | Nearly pathognomonic for SA when combined with appropriate iron studies. IDA gives a uniform microcytic picture; thalassemia trait gives uniform microcytosis with target cells. [1][5] |
| Pappenheimer bodies | Small, irregular iron-containing inclusions in mature RBCs, visible on Wright stain, confirmed by Prussian blue | Represent iron aggregates that escaped the reticuloendothelial system. Seen in SA, post-splenectomy, and lead poisoning. |
| Basophilic stippling | Blue dots in RBCs representing aggregated ribosomes/RNA | Particularly prominent in lead poisoning (lead inhibits pyrimidine-5'-nucleotidase → ribosomes cannot be degraded). Also seen in thalassemia and some SA. |
| Dysplastic neutrophils | Pseudo-Pelger-Huet anomaly (bilobed neutrophils), hypogranulation | Suggests MDS-RS. Presence of pseudo-Pelger-Huet cells: PMN leukocytes with hyposegmented or hypersegmented nuclei is characteristic of MDS on PBS. [9] |
| Oval macrocytes | Large, oval-shaped RBCs | If present with hypersegmented neutrophils → think B12/folate deficiency, not SA |
| Blasts | Immature myeloid/lymphoid cells | If ≥ 20% → AML, not MDS. Blasts: always abnormal; if ≥ 20%, diagnostic of acute leukaemia. [10] |
3.3 Bone Marrow Examination — The Definitive Investigation
Bone marrow aspirate site: typically posterior iliac crest. Aspirate for smear permits cytology examination, flow cytometry and genetic studies. Trephine biopsy permits histological examination (marrow cellularity, architectural details, marrow fibrosis, bone structure). [10][13]
The bone marrow examination is mandatory for confirming sideroblastic anemia and for distinguishing it from other causes of cytopenia.
What is the hematological feature that can be determined by Perl's stain? — Sideroblastic anemia. Ring sideroblasts → the RBC have a ring of iron-laden mitochondria around the nucleus. And since iron is blue, you will see a blue ring around the nucleus. [5]
| Finding | Interpretation |
|---|---|
| Ring sideroblasts ≥ 15% (or ≥ 5% with SF3B1 mutation) | Diagnostic of sideroblastic anemia |
| Increased diffuse iron stores (strong blue staining of macrophage iron) | Iron overload — expected in SA. Contrasts with absent iron stores in IDA. |
| Normal sideroblasts (< 5 granules, randomly distributed) | Normal finding in up to 30-50% of erythroblasts. Not pathological. |
How to perform and interpret Prussian blue stain:
- BM aspirate smear is fixed
- Treated with potassium ferrocyanide + hydrochloric acid (the "Prussian blue" reaction)
- Fe³⁺ in tissue reacts with ferrocyanide → ferric ferrocyanide = intense blue precipitate
- Count at least 100 erythroblasts and calculate the percentage with ≥ 5 perinuclear granules forming a ring around ≥ 1/3 of the nucleus
- Report as "X% ring sideroblasts"
| Feature | Finding in SA | Significance |
|---|---|---|
| Cellularity | Hypercellular in MDS-RS (immature abnormal cells do not release into circulation → marrow trying hard but failing) [9] | Contrasts with aplastic anemia which is hypocellular |
| Erythroid series | Dyserythropoiesis: megaloblastoid changes, nuclear budding, nuclear bridging, multinucleation | Reflects disordered erythroid maturation (ineffective erythropoiesis) |
| Myeloid series | ± Hypogranulation, pseudo-Pelger-Huet anomaly (if MDS) | Multi-lineage dysplasia suggests MDS-RS-MLD |
| Megakaryocytes | ± Small, hypolobulated (if MDS); large, hyperlobulated (if MDS/MPN-RS-T) | Megakaryocyte morphology helps differentiate MDS-RS from MDS/MPN-RS-T |
| Blast count | < 5% in MDS-RS; must be < 20% to exclude AML [9][12] | If ≥ 20% blasts → AML, not MDS |
Hypercellular (hyperplastic) bone marrow — immature abnormal cells do not release into circulation. Presence of dysplastic cells ≥ 1 myeloid series. ↑ Immature cells and blasts — may progress into AML. [9]
| Feature | Purpose |
|---|---|
| Overall cellularity | Confirms hypercellularity (MDS-RS) vs. hypocellularity (aplastic anemia) |
| Architecture | Assess for fibrosis (if present → consider primary myelofibrosis overlap) |
| Immunohistochemistry | CD34 staining to quantify blasts; can help if aspirate is suboptimal |
3.4 Cytogenetic and Molecular Studies
These are essential for classification, prognosis, and treatment planning in acquired (clonal) SA.
Cytogenetic study (with karyotyping): Abnormal karyotyping is seen in 40–50% of MDS cases. Most common changes are del(5q), del(7q), del(20q), missing chromosome 7 (-7) and additional chromosome 8 (+8). [9]
| Finding | Significance |
|---|---|
| Normal karyotype | Common in MDS-RS (many have SF3B1 mutation but normal cytogenetics) |
| del(5q) | If isolated → classify as MDS with isolated del(5q) (not MDS-RS). Good prognosis, responds to lenalidomide. |
| del(7q) / -7 | Poor prognosis |
| Complex karyotype (≥ 3 abnormalities) | Very poor prognosis |
| Test | Target | Significance |
|---|---|---|
| SF3B1 mutation | Spliceosome gene | Found in ~80-90% of MDS-RS. Favorable prognosis. Allows ring sideroblast threshold of ≥ 5% (instead of 15%) for MDS-RS diagnosis. [7][9] |
| JAK2 V617F | Myeloproliferative marker | If present with SF3B1 → suggests MDS/MPN-RS-T |
| CALR / MPL | Myeloproliferative markers | Alternative MPN driver mutations in MDS/MPN-RS-T |
| TP53 | Tumor suppressor | Poor prognosis if mutated in MDS |
| ASXL1, EZH2, RUNX1 | Epigenetic regulators | Adverse prognostic markers in MDS |
| ALAS2 | ALA synthase 2 | Pathogenic variant confirms X-linked hereditary SA |
| SLC25A38, ABCB7, GLRX5 | Mitochondrial genes | Confirm specific hereditary SA subtypes |
Molecular genetic testing: Prognostic implication in patients with MDS having TP53, EZH2, ETV6, RUNX1, ASXL1 mutation. [9]
| Test | When to Order | Finding |
|---|---|---|
| Serum pyridoxine (B6) level | Suspected nutritional deficiency or drug-induced (INH) | ↓ in B6 deficiency or INH-induced depletion |
| Blood lead level | Suspected lead exposure (occupational Hx, basophilic stippling, abdominal colic, wrist drop) | ↑ (> 25 µg/dL diagnostic in adults) |
| Free erythrocyte protoporphyrin (FEP) | Lead poisoning, IDA | ↑ in lead poisoning (protoporphyrin accumulates because ferrochelatase is inhibited). Also ↑ in IDA (less iron available for ferrochelatase). |
| Urinary ALA and coproporphyrin | Lead poisoning | ↑ ALA (ALA dehydratase inhibited → ALA accumulates); ↑ coproporphyrin |
| Serum copper, ceruloplasmin | Suspected copper deficiency (post-gastric bypass, zinc excess) | Both ↓ |
| Serum zinc | Zinc-induced copper deficiency | ↑ |
| Pyridoxine trial | All newly diagnosed hereditary SA; suspected B6-related cause | Reticulocyte rise + Hb improvement within 1-3 months = pyridoxine-responsive. Give 50-200 mg/day for at least 3 months. |
| MRI T2 of liver and heart* | Iron overload assessment (transfusion-dependent or long-standing SA) | Non-invasive and accurate for iron overload assessment — low T2* signal (short T2*) = high iron content. Replaces liver biopsy. [14] |
| Flow cytometry for CD55/CD59 | If coexistent PNH suspected (hemolysis, thrombosis) | ↓ CD55/CD59 on RBCs = PNH clone. MDS and PNH can coexist. [2][13] |
| Chromosome breakage analysis with diepoxybutane (DEB) | Pediatric SA / aplastic anemia (to rule out Fanconi anemia) | ↑ chromosome breaks = Fanconi anemia [2] |
Iron overload is a major source of morbidity in chronic SA (both from ineffective erythropoiesis-driven absorption and from transfusions). Monitoring is essential.
MRI T2 of the liver and heart → non-invasive and accurate. Replaces liver biopsy and ferritin (which has too many confounding factors).* [14]
| Modality | Target | Interpretation |
|---|---|---|
| Serum ferritin | Surrogate marker of total body iron | ↑ ferritin = iron overload. But caveat: acute phase reactant (false elevation in infection/inflammation). |
| MRI T2 liver* | Hepatic iron concentration | T2* < 6.3 ms (or liver iron > 7 mg/g dry weight) = significant overload requiring chelation |
| MRI T2 heart* | Cardiac iron | T2* < 20 ms = cardiac iron loading; T2* < 10 ms = severe, high risk of heart failure |
| Echocardiography | Cardiac function | To detect early cardiomyopathy from iron overload |
| Endocrine workup | End-organ iron damage | Fasting glucose/HbA1c (pancreatic iron → diabetes), TFTs, sex hormones, IGF-1 |
The following table summarizes the expected findings across all major investigations for each type of SA:
| Investigation | Hereditary SA (XLSA) | MDS-RS | Drug/Toxin-Induced SA | Lead Poisoning |
|---|---|---|---|---|
| MCV | ↓ (microcytic) | ↑ (macrocytic) | Variable | ↓ (microcytic) |
| RDW | ↑↑ (dimorphic) | ↑ | ↑ | ↑ |
| Reticulocytes | ↓ | ↓ | ↓ or N | ↓ |
| Serum Fe | ↑ | ↑ or N | ↑ or N | N or ↑ |
| Ferritin | ↑ | ↑ or N | ↑ or N | N |
| TIBC | N or ↓ | N or ↓ | N | N |
| PBS | Dimorphic, Pappenheimer bodies | Dysplastic WBCs, oval macrocytes | Variable | Basophilic stippling |
| BM Prussian blue | Ring sideroblasts, ↑ iron stores | Ring sideroblasts ≥ 15% (or ≥ 5% + SF3B1), dysplasia, hypercellular | Ring sideroblasts (may be transient) | Ring sideroblasts |
| Cytogenetics | Normal | ± del(5q), del(7q), +8 | Normal | Normal |
| SF3B1 | Negative | Positive ~80-90% [7][9] | Negative | Negative |
| Special test | ALAS2 mutation | IPSS-R/IPSS-M scoring | Blood lead, B6 level, Cu/Zn | ↑ blood lead, ↑ FEP, ↑ urine ALA |
High Yield Summary — Diagnostic Approach
-
Gold standard for SA diagnosis: Bone marrow aspirate with Perl's Prussian Blue stain showing ≥ 15% ring sideroblasts (or ≥ 5% with SF3B1 mutation for MDS-RS) [5][9]
-
Key iron studies pattern: ↑ serum iron, ↑ ferritin, N/↓ TIBC, ↑ TSAT — opposite to IDA
-
PBS clues before BM: Dimorphic red cells + Pappenheimer bodies + high RDW → strongly suspect SA
-
Top differential for SA: always think MDS — especially in elderly patients [5]
-
SF3B1 mutation: Present in ~80-90% of MDS-RS; favorable prognosis; lowers RS threshold to 5%
-
Reversible causes must be excluded FIRST: Check B6, B12/folate, copper, lead level, drug history before labeling as MDS
-
Iron overload monitoring: MRI T2 of liver and heart* is the standard — replaces liver biopsy and ferritin [14]
-
BM for aplastic anemia shows hypocellular marrow with no dysplasia; BM for MDS-RS shows hypercellular marrow with dysplasia and ring sideroblasts — completely opposite pictures despite both causing cytopenia [2][9]
Active Recall - Diagnostic Criteria, Algorithm, and Investigations for Sideroblastic Anemia
References
[1] Lecture slides: GC 076. Pallor_diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf; Block A - Pallor_ diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf [2] Lecture slides: Block A - Family history of anaemia_ inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf; GC 047. Family history of anaemia.pdf [3] Senior notes: Block A - Hematology Interactive Tutorial.pdf [5] Lecture slides: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf [7] Lecture slides: GC 060. High white cell count.pdf; Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf [9] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (MDS section); MBBS Final MB (Pediatrics) (Felix PY Lai).pdf [10] Senior notes: Ryan Ho Haemtology.pdf (MDS and AML sections) [12] Senior notes: Maksim Medicine Notes.pdf (Haematology section) [13] Senior notes: Ryan Ho Fundamentals.pdf (Haematological investigations); Ryan Ho Haemtology.pdf (Bone marrow examination) [14] Senior notes: Block A - Fever after a blood transfusion_ transfusion and related problems.pdf (Transfusion hemosiderosis section)
Management Algorithm and Treatment Modalities for Sideroblastic Anemia
Before diving into specifics, let's establish the conceptual framework. Managing sideroblastic anemia (SA) rests on four pillars:
- Identify and treat the underlying cause — especially reversible causes (drugs, toxins, nutritional deficiency)
- Correct the anemia — pyridoxine trial, erythropoiesis-stimulating agents, transfusion support
- Prevent and manage iron overload — the silent killer in chronic SA
- Disease-specific therapy — for clonal SA (MDS-RS), targeted agents and potentially allogeneic HSCT
The management strategy differs dramatically based on whether the SA is reversible, hereditary, or clonal (MDS-RS). This is why the diagnostic workup (establishing the cause) is so critical before committing to a treatment plan.
Sideroblastic anemia management: X-linked → high-dose pyridoxine (co-enzyme for the mutated enzyme). Acquired → treat underlying cause, EPO, G-CSF, transfusion. [12]
3. Treatment Modalities — Detailed Breakdown
3.1 Pillar 1: Treat the Underlying Cause (Reversible SA)
This is the most satisfying part of managing SA — if you catch a reversible cause, the patient can be cured completely.
| Offending Drug | Action | Mechanism of SA | Expected Recovery |
|---|---|---|---|
| Isoniazid (INH) | Stop if possible, or continue with pyridoxine 50-200 mg/day supplementation | INH inhibits pyridoxal phosphase → depletes pyridoxal phosphate (active B6) → ALAS2 dysfunction | Ring sideroblasts resolve within 1-2 weeks of B6 supplementation. If INH must continue (TB treatment), co-prescribe B6 prophylactically (standard practice: 10-25 mg/day prevention; 50-200 mg/day treatment) [1] |
| Chloramphenicol | Stop drug | Inhibits mitochondrial protein synthesis (targets 70S ribosome) | Reversible within days to weeks |
| Linezolid | Stop drug or shorten course | Same mechanism as chloramphenicol | Reversible; typically occurs with prolonged courses ( > 2 weeks) |
| Cycloserine | Stop drug, supplement B6 | Pyridoxine antagonist | Reversible with B6 supplementation |
High Yield — INH and B6 in Hong Kong
INH is the most important drug cause of SA in HK due to the TB burden. Standard practice: always co-prescribe pyridoxine 10-25 mg/day with INH prophylactically. If SA develops, increase to therapeutic dose (50-200 mg/day). If INH must continue, the SA typically resolves with adequate B6 supplementation alone. [1]
| Toxin | Action | Key Points |
|---|---|---|
| Ethanol (alcohol) | Abstinence + B6 and folate supplementation | Alcohol is directly toxic to mitochondria AND depletes B6 and folate. Ring sideroblasts from alcohol disappear within days of abstinence. [1] This is one of the fastest-resolving forms of SA. Also address liver disease, nutritional rehabilitation. |
| Lead | Remove exposure source. Chelation therapy for symptomatic patients or blood lead > 45 µg/dL (children) or > 70 µg/dL (adults with symptoms) | Chelation agents: Succimer (DMSA) orally, CaNa₂EDTA IV, dimercaprol (BAL) IM for severe cases. Lead inhibits ALA dehydratase and ferrochelatase — chelation binds lead and promotes renal excretion. |
| Zinc excess | Stop zinc supplementation. Supplement copper (copper gluconate 2-8 mg/day) | Zinc induces metallothionein in enterocytes → traps copper → copper malabsorption. Stopping zinc allows copper levels to recover; copper supplementation accelerates recovery. |
| Deficiency | Replacement | Monitoring |
|---|---|---|
| Pyridoxine (B6) | Oral pyridoxine 50-200 mg/day | Reticulocyte response in 1-2 weeks; Hb rise ~1 g/dL per 1-2 weeks. Repeat B6 level. |
| Copper | Copper gluconate 2-8 mg/day orally, or IV copper if severe | Serum copper and ceruloplasmin q4-8 weeks until normalized. Expect hematological response in 4-8 weeks. |
| Folate | Folic acid 1-5 mg/day | Folate supplementation is generally recommended for any form of hemolysis or ineffective erythropoiesis — to replenish the raw material. [2] |
3.2 Pillar 2: Correct the Anemia
Why try pyridoxine in almost every case?
Because pyridoxal phosphate is the essential cofactor for ALAS2 (the rate-limiting enzyme of heme synthesis). Many cases of SA — whether hereditary (ALAS2 mutations affecting the B6 binding site) or acquired (drug-induced, nutritional) — are at least partially pyridoxine-responsive. A pyridoxine trial is simple, safe, and can avoid the need for transfusions.
X-linked sideroblastic anemia: high-dose pyridoxine (co-enzyme for the mutated enzyme). [12]
| Parameter | Details |
|---|---|
| Dose | 50-200 mg/day orally (some hereditary cases may need up to 300 mg/day) |
| Duration of trial | At least 3 months before declaring non-responsive |
| Monitoring | Reticulocyte count weekly for first 2-4 weeks; CBC q2-4 weeks; expect Hb rise within 1-3 months if responsive |
| Response criteria | ≥ 1-2 g/dL rise in Hb AND/OR significant reticulocyte response |
| If responsive | Continue lifelong at the lowest effective dose. Some patients achieve near-normal Hb. |
| If non-responsive | Move to other treatment modalities (ESA, luspatercept, transfusion) |
| Side effects | Generally well-tolerated. High-dose, long-term use ( > 200 mg/day for years) can paradoxically cause peripheral neuropathy. |
| Contraindications | None absolute. Use caution with very high doses ( > 500 mg/day) due to neurotoxicity risk. |
Exam Pearl
Not all ALAS2 mutations are pyridoxine-responsive. Only those affecting the B6 binding site of the enzyme respond well. Mutations affecting the catalytic domain or other structural regions are typically non-responsive. A 3-month trial is the standard to determine responsiveness.
ESAs are used in MDS-RS and some chronic hereditary SA where pyridoxine is ineffective and the patient is symptomatic from anemia but not yet transfusion-dependent (or low transfusion burden).
ESA for MDS-RS: indicated for isolated anaemia with EPO ≤ 500 mU/mL. [10]
Rationale: In MDS-RS, endogenous EPO may be insufficient to overcome the ineffective erythropoiesis. Supraphysiological doses of EPO/ESA can "push" the remaining functional erythroid precursors to produce more red cells.
| Parameter | Details |
|---|---|
| Agents | Erythropoietin (epoetin alfa/beta), Darbepoetin alfa [15] |
| Best response predicted by | Serum EPO ≤ 500 mU/mL AND low transfusion burden ( < 2 units/month) |
| Dose | Epoetin alfa 40,000-60,000 IU SC weekly; Darbepoetin 150-300 µg SC q2-3 weeks |
| Response rate | ~40-60% in lower-risk MDS-RS |
| Duration to assess | 8-12 weeks minimum |
| Monitoring | CBC q2-4 weeks. Target Hb ~10-12 g/dL (avoid overshooting → thrombotic risk) |
| Contraindications/cautions | Uncontrolled hypertension, prior thromboembolic events, pure red cell aplasia from ESA antibodies |
Functional iron deficiency (hypochromic reticulocytes) may limit ESA response — ensure adequate iron delivery. Unlike IDA, the issue in SA is not absence of iron but its maldistribution. Paradoxically, some ESA-treated MDS patients may still benefit from IV iron to optimize transferrin saturation. [15]
Luspatercept is a recombinant fusion protein that acts as a ligand trap for TGF-β superfamily members (specifically GDF11 and activin A). These ligands normally inhibit late-stage erythroid maturation via the Smad2/3 signaling pathway. By neutralizing them, luspatercept promotes terminal erythroid differentiation.
Targeted therapy for low-risk MDS with ring sideroblasts: luspatercept. [10]
The name: "Lus-pater-cept" — think of it as "intercepting" the TGF-β ligands that are blocking erythropoiesis. It was specifically designed for conditions with ineffective erythropoiesis.
| Parameter | Details |
|---|---|
| Mechanism | Binds GDF11/activin A → blocks aberrant Smad2/3 signaling → corrects ineffective erythropoiesis |
| Indication | MDS-RS (with or without SF3B1 mutation) in lower-risk MDS patients who are transfusion-dependent or ESA-refractory [10] |
| Key trial | MEDALIST trial (phase 3) — showed significant transfusion independence and Hb response in MDS-RS patients. COMMANDS trial — luspatercept vs. ESA as first-line in lower-risk MDS-RS (showed superiority over ESA). |
| Dose | 1.0 mg/kg SC q3 weeks; titrate up to 1.75 mg/kg if inadequate response |
| Response rate | ~38% achieve transfusion independence (MEDALIST); ~59% with first-line use (COMMANDS) |
| Side effects | Fatigue, diarrhea, nausea, bone pain. Hypertension. Thromboembolic events (uncommon). |
| Contraindications | Pregnancy (teratogenic in animal studies — requires contraception). Use with caution if active thromboembolic disease. |
Luspatercept: target TGF-β ligand → block aberrant Smad2/3 signalling → correct ineffective erythropoiesis. [12]
High Yield — Luspatercept vs. ESA in MDS-RS
Based on the COMMANDS trial results, luspatercept is now increasingly used as first-line for lower-risk MDS-RS with symptomatic anemia, particularly when SF3B1 mutation is present. Previously, ESAs were first-line, with luspatercept reserved for ESA failures. Current guidelines (NCCN 2025) support either approach, but luspatercept has shown superiority in transfusion independence.
For patients who are non-responsive to pyridoxine, ESA, and luspatercept (or who have severe symptomatic anemia), chronic red cell transfusion becomes necessary.
Iron in 500 mL of blood = 250 mg — 8 months' worth of dietary iron. The body does not have a good mechanism of iron excretion → prone to iron overload. Iron overload → toxic to the heart. [3]
| Parameter | Details |
|---|---|
| Indication | Symptomatic anemia unresponsive to other therapies; Hb < 7 g/dL (or < 8-9 g/dL with cardiac disease) |
| Target | Maintain Hb at a level that controls symptoms (usually 8-10 g/dL). Do NOT aim for normal Hb — this would require excessive transfusion and worsen iron overload. |
| Transfusion type | Leukodepleted, extended crossmatched red blood cells — to minimize alloimmunization and febrile non-hemolytic transfusion reactions [12] |
| Frequency | Typically every 2-4 weeks depending on transfusion requirement |
| Monitoring | Pre-transfusion Hb, ferritin q3 months, type and screen |
| Complication | Transfusion iron overload (see Pillar 3 below). Each unit of packed RBCs delivers ~200-250 mg of elemental iron that the body cannot excrete. |
3.3 Pillar 3: Prevent and Manage Iron Overload
Iron overload is the major cause of morbidity and mortality in chronic SA. It occurs through two mechanisms:
- Ineffective erythropoiesis → increased erythroferrone → suppresses hepcidin → increased intestinal iron absorption (even without transfusions)
- Transfusional iron loading → each unit adds ~200-250 mg iron with no physiological excretion mechanism
How to get rid of iron? Chelation → Desferrioxamine (DFO), DFP and Deferasirox. Bind to iron, excrete from urine and feces. [3]
| Agent | Route | Dose | Key Features | Side Effects | Contraindications |
|---|---|---|---|---|---|
| Deferoxamine (Desferal, DFO) | SC infusion (8-12h) 5-7 days/week; or IV | 20-50 mg/kg/day | Gold standard. Long track record. Excretes iron in urine (reddish-orange) and feces. | Ototoxicity (sensorineural hearing loss), retinal changes, ARDS, injection site reactions, compliance issues [12] | Severe renal impairment. Poor compliance is the main practical limitation — patients often dislike the long SC infusion. |
| Deferiprone (Ferriprox, DFP) | PO TID | 75-100 mg/kg/day in 3 divided doses | Penetrates cardiac cells better than DFO — particularly effective for cardiac iron overload. Often used in combination with DFO. | Agranulocytosis (1-2% — MUST monitor weekly ANC), arthropathy, GI upset, orange/brown urine [12] | Neutropenia/agranulocytosis history. Requires weekly CBC monitoring. |
| Deferasirox (Exjade/Jadenu) | PO once daily | 14-28 mg/kg/day (Jadenu dispersible tablets); 20-40 mg/kg/day (Exjade) | Once-daily dosing → best compliance. Excretes iron primarily in feces. | GI upset (nausea, diarrhea, abdominal pain), LFT/RFT derangements, hypersensitivity, rare hepatic/renal failure [12] | Severe hepatic or renal impairment (CrCl < 40 mL/min). Monitor LFT and RFT monthly. |
When to start chelation:
Iron chelation: indicated if ferritin > 1000 µg/L, positive findings in MRI T2 for liver/heart.* [12]
| Criterion | Threshold |
|---|---|
| Serum ferritin | > 1000 µg/L (persistently) |
| Liver iron concentration (MRI) | > 7 mg/g dry weight |
| Cardiac T2* (MRI) | < 20 ms |
| Transfusion burden | After ~20 units of packed RBCs (roughly 4000-5000 mg iron loaded) |
Monitoring during chelation:
MRI T2 of the liver and heart → non-invasive and accurate for iron overload assessment.* [14]
| Parameter | Frequency | Target |
|---|---|---|
| Serum ferritin | Every 3 months | 500-1000 µg/L (avoid over-chelation below 500 → iron depletion toxicity from chelator) |
| MRI T2 liver* | Annually | LIC 3-7 mg/g dry weight |
| MRI T2 heart* | Annually (if cardiac iron loading) | T2* > 20 ms |
| Audiometry + ophthalmology | Annually (if on DFO) | Monitor for ototoxicity and retinal toxicity |
| CBC | Weekly (if on DFP) | Monitor for agranulocytosis |
| LFT + RFT | Monthly (if on deferasirox) | Monitor for hepatic/renal toxicity |
In non-transfusion-dependent SA with significant iron overload (e.g., pyridoxine-responsive hereditary SA where Hb is maintained at adequate levels), phlebotomy can be used instead of chelation:
| Parameter | Details |
|---|---|
| Indication | Iron overload in non-transfusion-dependent SA with Hb ≥ 10 g/dL |
| Regimen | 250-500 mL every 1-2 weeks initially; then every 1-3 months for maintenance |
| Target | Ferritin 50-100 µg/L |
| Advantage | Simpler, cheaper, fewer side effects than chelation |
| Contraindication | Symptomatic anemia; Hb too low to tolerate blood removal |
3.4 Pillar 4: Disease-Specific Therapy (MDS-RS)
Management of MDS: NOT ALL MDS require treatment. Prognosis is very heterogeneous. No current Tx curative (except allo-HSCT). No evidence that treatment of asymptomatic patients can prolong survival → main goal to control symptoms + increase QoL. [10]
Before deciding on treatment intensity, all MDS-RS patients must be risk-stratified:
| Scoring System | Components | Purpose |
|---|---|---|
| IPSS-R (Revised International Prognostic Scoring System) | Cytogenetics, BM blast %, Hb, ANC, platelet count | Stratifies into Very Low / Low / Intermediate / High / Very High risk categories |
| IPSS-M (Molecular) | Incorporates molecular mutations (SF3B1, TP53, ASXL1, etc.) into IPSS-R framework | More refined prognostication. SF3B1-mutated MDS-RS is generally lower risk. |
| Treatment Step | Agent/Approach | When to Use |
|---|---|---|
| 1. Watch and wait | Regular CBC monitoring q1-3 months | If asymptomatic, Hb stable, no transfusion need |
| 2. ESA | Epoetin / Darbepoetin | Symptomatic anemia with EPO ≤ 500 mU/mL [10] |
| 3. Luspatercept | SC q3 weeks | MDS-RS specific; first-line or ESA-refractory [10] |
| 4. Transfusion + chelation | PRBCs ± DFO/DFP/deferasirox | If ESA + luspatercept fail |
| 5. Lenalidomide | 10 mg/day PO days 1-21 q28 days | Only if del(5q) is present (not standard for MDS-RS without del(5q)) [10] |
| 6. Hypomethylating agents | Azacitidine 75 mg/m² SC × 7 days q28 days; Decitabine | For lower-risk MDS with bi/pancytopenia unresponsive to above [10] |
| 7. Immunosuppressive therapy | ATG + cyclosporine | Selected patients (younger, hypocellular marrow, PNH clone) |
| Treatment | Details |
|---|---|
| Hypomethylating agents (HMA) | Azacitidine shown to increase survival in higher-risk MDS. Not curative but delays progression to AML. [10] |
| Allogeneic HSCT | Only potentially curative treatment. For higher-risk MDS in fit patients ( < 65-70 years) with suitable donor. [7][10] |
Allogeneic HSCT — Indications and Considerations:
Indications for allogeneic HSCT: MDS — high risk. [7]
| Parameter | Details |
|---|---|
| Indication | Higher-risk MDS (IPSS-R > 3.5), particularly with adverse cytogenetics or TP53 mutation |
| Age limit | Generally < 65-70 years (biological age), but expanding with reduced-intensity conditioning |
| Donor | HLA-matched sibling (ideal) > matched unrelated donor > haploidentical |
| Conditioning | Myeloablative (younger, fit) or reduced-intensity (older, comorbidities) |
| Outcome | 30-50% long-term disease-free survival depending on disease risk and patient fitness |
| Risks | GvHD, infection, graft failure, transplant-related mortality (10-30%) |
| Measure | Rationale |
|---|---|
| Folate supplementation (1-5 mg/day) | Increased folate consumption from ineffective erythropoiesis and chronic hemolysis. Generally recommended for any form of hemolysis — replenish the raw material. [2] |
| Infection prevention | Neutropenia from MDS predisposes to infection. Vaccinations as appropriate. Antibiotics/antifungals if febrile neutropenia. |
| G-CSF | For severe neutropenia with recurrent infections. Not routinely used. |
| Platelet transfusion | If thrombocytopenia with active bleeding or platelet < 10 × 10⁹/L |
| Avoid iron supplementation | Patients are already iron-loaded — exogenous iron would worsen organ damage |
Critical Error to Avoid
Never give iron supplements to a patient with sideroblastic anemia! The iron studies (raised ferritin, raised serum iron) might superficially resemble "adequate iron," but the reality is the patient is iron-overloaded. Adding more iron accelerates organ damage (cardiac, hepatic, endocrine). The only scenario where iron might be considered is in an MDS-RS patient on ESA with documented functional iron deficiency (transferrin saturation < 20% despite elevated ferritin) — and this requires specialist guidance.
| Subtype | First-Line | Second-Line | Definitive |
|---|---|---|---|
| XLSA (ALAS2) | Pyridoxine trial 50-200 mg/day (many are B6-responsive) [12] | Transfusion + iron chelation if non-responsive | Allogeneic HSCT (rare; reserved for severe transfusion-dependent cases) |
| SLC25A38 | Pyridoxine trial (usually non-responsive) | Transfusion + chelation | Allogeneic HSCT [7] (best option for severe cases in young patients) |
| XLSA with ataxia (ABCB7) | Supportive (no specific therapy for neurological component) | Transfusion + chelation | HSCT (limited data) |
| Pearson syndrome | Supportive (transfusion, pancreatic enzyme replacement) | — | Usually fatal in infancy; survivors may evolve to Kearns-Sayre syndrome |
| TRMA (SLC19A2) | High-dose thiamine (25-75 mg/day) — name tells you: thiamine-responsive | — | Lifelong thiamine supplementation |
| SA Category | Remove Cause | Pyridoxine | ESA | Luspatercept | Transfusion | Chelation | HMA | HSCT |
|---|---|---|---|---|---|---|---|---|
| Drug-induced | ✅ (primary) | ✅ | — | — | If severe | Rarely needed | — | — |
| Alcohol | ✅ (abstinence) | ✅ + folate | — | — | If severe | Rarely needed | — | — |
| Lead | ✅ + chelation | — | — | — | If severe | Lead chelation (not iron chelation) | — | — |
| Nutritional (B6, Cu) | ✅ (supplement) | ✅ | — | — | If severe | Rarely needed | — | — |
| Hereditary (XLSA) | N/A | ✅ (first-line) | ± | — | If non-responsive | ✅ if chronic | — | Severe cases |
| MDS-RS (lower risk) | Exclude reversible causes first | — | ✅ | ✅ | If refractory | ✅ | ± | Rarely |
| MDS-RS (higher risk) | — | — | — | — | ✅ | ✅ | ✅ | ✅ |
| Parameter | Frequency | Target/Action |
|---|---|---|
| CBC | q1-3 months (stable); q2-4 weeks (active treatment) | Monitor Hb response, cytopenias |
| Iron studies (ferritin, TSAT) | q3 months | Start chelation if ferritin > 1000 |
| MRI T2 liver* | Annually | LIC < 7 mg/g dry weight [14] |
| MRI T2 heart* | Annually (if cardiac concern) | T2 > 20 ms* [14] |
| Endocrine workup | Annually (if iron overloaded) | Screen for DM, hypothyroidism, hypogonadism |
| BM biopsy | As clinically indicated (progression, new cytopenias) | Monitor for disease progression (MDS → AML if blasts ≥ 20%) |
| Reticulocyte count | q2-4 weeks during pyridoxine/ESA trial | Assess marrow response |
High Yield Summary — Management
Management of SA follows the underlying cause:
-
Reversible SA: Remove offending agent (INH, alcohol, lead, zinc) + supplement B6/copper/folate. Ring sideroblasts resolve rapidly.
-
Hereditary SA: Trial of high-dose pyridoxine (50-200 mg/day × 3 months). If responsive → lifelong B6. If non-responsive → transfusion + iron chelation ± HSCT.
-
MDS-RS (most common acquired): Risk-stratify with IPSS-R/IPSS-M.
- Lower risk: ESA (if EPO ≤ 500) → luspatercept (MDS-RS specific) → transfusion + chelation
- Higher risk: Hypomethylating agents (azacitidine) → allogeneic HSCT
-
Iron overload management: Critical in all chronic SA.
- Three chelators: DFO (SC/IV), deferiprone (PO), deferasirox (PO)
- Monitor with MRI T2 liver and heart*
- Start when ferritin > 1000 or LIC > 7 mg/g
-
NEVER give iron supplements to SA patients — they are already iron-overloaded.
-
Folate supplementation recommended for all chronic SA (compensates for increased folate consumption from ineffective erythropoiesis).
Active Recall - Management of Sideroblastic Anemia
References
[1] Lecture slides: GC 076. Pallor_diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf; Block A - Pallor_ diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf [2] Lecture slides: Block A - Family history of anaemia_ inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf; GC 047. Family history of anaemia.pdf [3] Senior notes: Block A - Hematology Interactive Tutorial.pdf [5] Lecture slides: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf [7] Lecture slides: GC 060. High white cell count.pdf; Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf [10] Senior notes: Ryan Ho Haemtology.pdf (MDS management section) [12] Senior notes: Maksim Medicine Notes.pdf (Haematology section — sideroblastic anemia, iron overload, MDS) [14] Senior notes: Block A - Fever after a blood transfusion_ transfusion and related problems.pdf (Transfusion hemosiderosis section) [15] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (ESA section)
Complications of Sideroblastic Anemia
Complications of sideroblastic anemia stem from three fundamental pathological processes that flow logically from the underlying disease:
- Chronic anemia → consequences of prolonged tissue hypoxia
- Iron overload (secondary hemochromatosis) → the major killer, caused by both ineffective erythropoiesis and chronic transfusions
- Clonal evolution → specific to MDS-RS, the risk of transformation to acute myeloid leukemia
Think of it this way: the bone marrow is broken, so erythroblasts die before maturing (ineffective erythropoiesis). The body responds by absorbing more iron from the gut (hepcidin suppression), but the marrow still can't use it. Meanwhile, the patient may need regular transfusions, each unit adding ~200-250 mg of iron that the body cannot excrete. Iron accumulates relentlessly in organs — liver, heart, endocrine glands — causing progressive damage over years.
1. Complications of Iron Overload (Secondary Hemochromatosis)
This is the single most important category of complications in sideroblastic anemia — and the leading cause of morbidity and mortality in transfusion-dependent patients.
Transfusion hemosiderosis — iron accumulation within: Liver → liver fibrosis and HCC; Endocrine organs → diabetes mellitus, growth retardation and hypogonadism; Heart → heart failure. [14]
Two converging mechanisms:
-
Increased intestinal iron absorption (even without transfusions):
- Ineffective erythropoiesis → erythroid precursors release erythroferrone → suppresses hepatic hepcidin production → ferroportin on enterocytes remains active → unregulated iron absorption from the gut
- This means a non-transfusion-dependent SA patient will still progressively iron-load over years
-
Transfusional iron loading:
Iron overload: 1st stage → Hemosiderosis (increased intracellular accumulation of iron, without evidence of toxicity). 2nd stage → Hemochromatosis (severe iron accumulation, with accompanying organ damage). [3]
| Organ | Complication | Pathophysiology | Clinical Features | Monitoring |
|---|---|---|---|---|
| Heart | Iron-mediated cardiomyopathy → heart failure [14] | Free iron catalyzes Haber-Weiss/Fenton reaction: Fe²⁺ + H₂O₂ → Fe³⁺ + OH⁻ + OH• (hydroxyl radical). These reactive oxygen species (ROS) damage myocardial cell membranes, mitochondria, and contractile proteins → myocyte death → both restrictive and dilated cardiomyopathy. | Dyspnea, orthopnea, peripheral edema, arrhythmias (especially atrial fibrillation). Cardiac iron overload is the leading cause of death in transfusion-dependent patients. | MRI T2 heart: T2 < 20 ms = cardiac iron loading; T2 < 10 ms = severe, high risk of heart failure*** [14]. ECG, echocardiography annually. |
| Liver | Liver fibrosis → cirrhosis → hepatocellular carcinoma (HCC) [14] | Iron accumulates in hepatocytes and Kupffer cells → ROS-mediated hepatocyte injury → stellate cell activation → collagen deposition → progressive fibrosis → cirrhosis. Chronic oxidative DNA damage → carcinogenesis → HCC. | Often asymptomatic until advanced. Hepatomegaly, deranged LFTs, eventually portal hypertension, ascites, variceal bleeding. HCC risk increases once cirrhosis is established. | MRI T2 liver annually. US hepatobiliary system q6 months for HCC screening if cirrhosis.* [16] Serum ferritin q3 months. |
| Pancreas | "Bronze diabetes" [14] | Iron deposits in pancreatic beta cells → oxidative damage → beta cell apoptosis → insulin deficiency → diabetes mellitus. Combined with peripheral insulin resistance from iron deposition in skeletal muscle. | Polyuria, polydipsia, weight loss, elevated fasting glucose/HbA1c. The "bronze" refers to concurrent skin hyperpigmentation from iron deposition. | Fasting glucose and HbA1c q6 months. |
| Pituitary | Hypogonadotropic hypogonadism [14] | Iron deposits in anterior pituitary gonadotrophs → impaired LH/FSH secretion → secondary hypogonadism. The pituitary is exquisitely sensitive to iron — often the first endocrine organ affected. | Loss of libido, erectile dysfunction (males), amenorrhea/oligomenorrhea (females), infertility, delayed puberty (children), loss of secondary sexual characteristics. | Sex hormones (testosterone, estradiol, LH, FSH) annually. |
| Thyroid | Hypothyroidism | Iron deposition in thyroid follicular cells → gland destruction | Fatigue, cold intolerance, weight gain, constipation, bradycardia | TFTs q6-12 months |
| Parathyroids | Hypoparathyroidism | Iron deposition in parathyroid glands → impaired PTH secretion | Hypocalcemia → tetany, muscle cramps, perioral tingling, QTc prolongation | Serum calcium, phosphate, PTH q6-12 months |
| Growth (pediatric) | Growth retardation [14] | Iron deposition in pituitary (GH deficiency) + general metabolic impact of chronic anemia and iron toxicity | Short stature, delayed bone age | Height velocity, IGF-1, bone age X-ray |
| Skin | Hyperpigmentation (bronze/slate-grey) | Iron deposition in dermal macrophages + stimulation of melanin synthesis by iron in the epidermis | Generalized skin darkening, particularly in sun-exposed areas, axillae, groin | Clinical examination |
| Joints | Hemochromatotic arthropathy | Iron deposition in synovium and articular cartilage → chondrocalcinosis (calcium pyrophosphate deposition) + synovial inflammation | Joint pain and stiffness, classically affecting 2nd and 3rd MCP joints ("iron fist"). Pseudogout attacks. | X-ray hands: chondrocalcinosis, squared-off bone ends, hook-like osteophytes [12] |
High Yield — Iron Overload Is the Major Killer
Cardiac iron overload is the leading cause of death in transfusion-dependent sideroblastic anemia (and thalassemia major). Iron chelation therapy has dramatically improved survival by preventing cardiac hemochromatosis. The heart is uniquely vulnerable because iron directly damages contractile proteins and disrupts the conduction system. MRI T2* of the heart is the key monitoring tool — a T2* < 10 ms is a medical emergency requiring intensive chelation. [14]
These are common to any chronic anemia but are worth listing systematically because they affect quality of life and can be life-threatening.
| Complication | Pathophysiology | Key Points |
|---|---|---|
| High-output cardiac failure | Chronic anemia → decreased O₂ carrying capacity → compensatory increase in cardiac output (tachycardia, increased stroke volume) → chronic volume overload → ventricular dilation → eventual systolic failure | This is distinct from iron-mediated cardiomyopathy. Both can coexist in SA patients, creating a "double hit" on the heart. |
| Exercise intolerance and fatigue | Tissue hypoxia → insufficient O₂ delivery to skeletal muscles during exertion | The most common symptom affecting quality of life |
| Cognitive impairment | Chronic cerebral hypoxia | More common in elderly patients with MDS-RS; may be mistaken for dementia |
| Impaired wound healing | O₂ is essential for collagen synthesis and immune function at wound sites | Relevant in surgical patients or those with concurrent DM from iron overload |
| Extramedullary hematopoiesis | When the bone marrow cannot meet erythrocyte demand, other organs (spleen, liver, rarely paravertebral soft tissue) resume their fetal hematopoietic role | Causes hepatosplenomegaly, potential spinal cord compression from paravertebral masses (rare). Splenomegaly leads to secondary hypersplenism → worsened cytopenia (vicious cycle). |
Ineffective erythropoiesis (intramedullary death of erythroid precursors) has its own set of downstream consequences beyond just anemia:
| Complication | Pathophysiology | Clinical Significance |
|---|---|---|
| Elevated LDH and unconjugated bilirubin | Dying erythroblasts release intracellular LDH and hemoglobin → hemoglobin catabolized to unconjugated bilirubin | May be confused with hemolytic anemia, but reticulocytes are low (not elevated) because the cells die before reaching the reticulocyte stage. Intramedullary hemolysis DDx: Pernicious anemia, Thalassemia major, MDS. [1] |
| Gallstones (pigment stones) | Chronic elevation of unconjugated bilirubin → increased biliary excretion of bilirubin → precipitation as calcium bilirubinate stones in gallbladder | Patients may present with biliary colic, cholecystitis, or obstructive jaundice. Monitor with US hepatobiliary system q2 years [16] |
| Folate depletion | Rapid but futile erythroid precursor turnover → increased folate consumption for DNA synthesis | Can develop superimposed megaloblastic anemia if folate not supplemented → worsening the anemia further. Folate supplementation is generally recommended for any form of hemolysis/ineffective erythropoiesis — to replenish the raw material. [2] |
| Paradoxical iron overload without transfusion | Erythroferrone from expanded erythroid precursors → hepcidin suppression → unregulated intestinal iron absorption | Even non-transfusion-dependent SA patients can develop clinically significant iron overload over years |
Sideroblastic anemia may be an indicator/manifestation of underlying myelodysplastic syndrome. [5]
MDS-RS is a clonal stem cell disorder and therefore carries an inherent risk of progression to acute myeloid leukemia (AML).
| Parameter | Details |
|---|---|
| Mechanism | Accumulation of additional somatic mutations in the MDS clone → increasingly dysplastic and proliferative → blast count rises above 20% → meets criteria for AML |
| Risk in MDS-RS with SF3B1 | Low: approximately 5-10% lifetime risk of AML transformation. SF3B1-mutated MDS-RS is one of the most indolent MDS subtypes. |
| Risk in MDS-RS without SF3B1 | Higher than with SF3B1, especially if adverse cytogenetics (del(7q), complex karyotype) or adverse molecular features (TP53, ASXL1, RUNX1 mutations) |
| Clinical clues to transformation | Worsening cytopenias despite treatment, new constitutional symptoms (fever, weight loss, night sweats), increasing blast percentage on PBS, new splenomegaly |
| Monitoring | Regular CBC q1-3 months. Repeat BM biopsy if clinical deterioration or rising blast count on PBS. |
| Implications | Once transformed to AML, treatment shifts to AML-directed therapy (intensive chemotherapy ± allogeneic HSCT). Prognosis is generally poor for secondary AML arising from MDS. |
Exam Pearl — MDS-RS and AML Transformation
MDS-RS with SF3B1 mutation has one of the lowest risks of AML transformation among all MDS subtypes (~5-10%). This favorable biology is why SF3B1 mutation is considered a good prognostic marker. However, if adverse mutations (TP53, ASXL1) coexist, the risk increases substantially. Always check molecular genetics for prognostication. [7][10]
5. Complications of Treatment
Treatment itself carries complications that must be monitored:
| Agent | Complications | Monitoring |
|---|---|---|
| Deferoxamine (DFO) | Ototoxicity (sensorineural hearing loss), retinal toxicity (night blindness, visual field loss), bone dysplasia with truncal shortening (pediatric), injection site reactions, Yersinia infection (iron-dependent pathogen), ARDS (rare) [16] | Audiometry and ophthalmology annually. Growth charts in children. |
| Deferiprone | Agranulocytosis (1-2% — potentially fatal), arthropathy, GI upset, orange/brown discoloration of urine [12] | Weekly CBC — monitor ANC. Stop immediately if ANC < 1.5 × 10⁹/L. |
| Deferasirox | GI upset (most common), hepatotoxicity (LFT derangement, rare fulminant hepatic failure), renal toxicity (increased creatinine, Fanconi syndrome), hypersensitivity, GI hemorrhage [12] | Monthly LFT and RFT. |
| Over-chelation | If chelation reduces iron stores excessively → iron depletion → worsened anemia, neutropenia, ototoxicity, visual toxicity | Monitor ferritin — do not target below 500 µg/L. Temporarily hold chelation if ferritin drops below this level. |
For long-term transfusion patients such as thalassemia and MDS, they will inevitably develop iron overload. [14]
| Complication | Mechanism | Prevention/Management |
|---|---|---|
| Iron overload (discussed above) | Cumulative transfusional iron loading | Iron chelation |
| Alloimmunization | Recipient develops antibodies against donor RBC antigens → increasingly difficult crossmatching, delayed hemolytic transfusion reactions | Extended phenotype matching, leukodepletion |
| Transfusion-transmitted infections | HBV, HCV, HIV (rare with modern screening) | Infection screen q6 months: HIV, HBV, HCV [16] |
| Febrile non-hemolytic transfusion reactions | Recipient antibodies against donor leukocyte antigens | Leukodepleted blood products, pre-medication with paracetamol |
| Volume overload | Rapid infusion in elderly patients with compromised cardiac function | Slow transfusion rate, diuretics pre/post-transfusion |
Complications of HSCT: (1) Related to high-dose chemotherapy — infection, hemorrhage, veno-occlusive disease of liver; (2) Related to allogeneic HSCT — graft-versus-host disease (acute or chronic), graft rejection; (3) Late/long-term effects — cataract, immunodeficiency, endocrine dysfunction and infertility, secondary malignancy; (4) Relapse of disease. [7]
| Timing | Complications |
|---|---|
| Early ( < 1 year) | Mucositis, neutropenic infections (bacterial/fungal), hemorrhage, veno-occlusive disease (VOD) of liver, acute GvHD, graft rejection |
| Late ( > 1 year) | Chronic GvHD, infections (encapsulated bacteria, CMV reactivation), cardiovascular disease, endocrine dysfunction (DM, hypothyroidism, hypogonadism), infertility, osteoporosis, cataracts (from TBI), secondary malignancies (MDS, AML, solid tumors) |
| Underlying Cause | Specific Complications Beyond SA |
|---|---|
| Lead poisoning | Encephalopathy (children), peripheral motor neuropathy (wrist drop/foot drop), abdominal colic, nephropathy, developmental delay (children) |
| Chronic alcoholism | Liver disease (fatty liver → hepatitis → cirrhosis), Wernicke-Korsakoff syndrome, peripheral neuropathy, pancreatitis, cardiomyopathy, social consequences |
| Copper deficiency | Myelopathy (resembles subacute combined degeneration), peripheral neuropathy, neutropenia (may be severe), osteoporosis |
| MDS (in general) | Recurrent infections (neutropenia), bleeding (thrombocytopenia), AML transformation |
| Category | Key Complications | Most Important Point |
|---|---|---|
| Iron overload | Cardiomyopathy, cirrhosis/HCC, diabetes, hypogonadism, hypothyroidism, arthropathy, skin pigmentation | Leading cause of death — prevent with chelation |
| Chronic anemia | High-output cardiac failure, fatigue, cognitive impairment, extramedullary hematopoiesis | Treat anemia with pyridoxine/ESA/luspatercept/transfusion |
| Ineffective erythropoiesis | Gallstones, folate depletion, paradoxical iron absorption | Supplement folate; monitor biliary |
| Clonal evolution (MDS-RS) | AML transformation (~5-10% with SF3B1) | Monitor CBC and BM; adverse mutations increase risk |
| Treatment-related | Chelator toxicity, transfusion complications, HSCT complications | Agent-specific monitoring schedules |
| Cause-specific | Lead → neuropathy/encephalopathy; alcohol → liver disease; copper deficiency → myelopathy | Treat the underlying cause |
High Yield Summary — Complications
-
Iron overload is the #1 cause of morbidity and mortality in chronic/transfusion-dependent SA. Cardiac iron overload is the leading cause of death.
-
Each unit of blood = ~200 mg iron; only 1 mg/day excreted. The body has no active iron excretion mechanism — chelation is the only medical way to remove excess iron.
-
Iron damages organs via the Fenton/Haber-Weiss reaction (iron catalyzes H₂O₂ → ROS → oxidative damage).
-
Organ damage pattern: Heart (cardiomyopathy) > Liver (cirrhosis/HCC) > Endocrine (DM, hypogonadism, hypothyroidism) > Joints (arthropathy) — pituitary is often the first endocrine organ affected.
-
MDS-RS with SF3B1 mutation has low AML transformation risk (~5-10%) — but adverse co-mutations (TP53, ASXL1) worsen prognosis.
-
Monitor with: MRI T2 heart and liver annually; ferritin q3 months; endocrine workup annually; US HBP q6 months (if cirrhosis for HCC screening).*
-
Always supplement folate in chronic SA (increased consumption from ineffective erythropoiesis).
-
Treatment complications: DFO → ototoxicity; Deferiprone → agranulocytosis (weekly ANC!); Deferasirox → hepatorenal toxicity.
Active Recall - Complications of Sideroblastic Anemia
References
[1] Lecture slides: GC 076. Pallor_diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf; Block A - Pallor_ diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf [2] Lecture slides: Block A - Family history of anaemia_ inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf; GC 047. Family history of anaemia.pdf [3] Senior notes: Block A - Hematology Interactive Tutorial.pdf [5] Lecture slides: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf [7] Lecture slides: GC 060. High white cell count.pdf; Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf [10] Senior notes: Ryan Ho Haemtology.pdf (MDS management and HSCT complications sections) [12] Senior notes: Maksim Medicine Notes.pdf (Haematology section — iron overload, chelation, MDS) [14] Senior notes: Block A - Fever after a blood transfusion_ transfusion and related problems.pdf (Transfusion hemosiderosis section) [16] Senior notes: Adrian Lui Pediatrics Notes.pdf (Thalassemia complications and monitoring section); Ryan Ho Haemtology.pdf (Thalassemia monitoring section)
High Yield Summary
Sideroblastic Anemia — Key Points:
-
Definition: Anemia characterized by ring sideroblasts in bone marrow — iron accumulates in mitochondria because heme synthesis is defective.
-
Pathophysiology: Defect in heme biosynthetic pathway (most commonly ALAS2 or its B6 cofactor) → iron enters mitochondria but cannot be used → mitochondrial iron overload + ineffective erythropoiesis.
-
Classification:
- Congenital: XLSA (ALAS2 mutation — most common hereditary), SLC25A38, ABCB7, Pearson syndrome
- Acquired clonal: MDS-RS (SF3B1 mutation in ~80-90%)
- Acquired reversible: INH, alcohol, lead, copper deficiency, B6 deficiency
-
Clinical Features: Anemia symptoms + iron overload signs (hepatomegaly, skin pigmentation, cardiomyopathy, diabetes, hypogonadism). Dimorphic blood film + Pappenheimer bodies.
-
Iron Studies: ↑ serum iron, ↑ ferritin, normal/↓ TIBC, ↑ transferrin saturation — opposite to IDA.
-
MCV: Variable! Microcytic in hereditary forms, macrocytic in MDS-RS, variable in drug-induced.
-
Diagnosis: Bone marrow aspirate with Prussian blue stain showing ≥ 15% ring sideroblasts (or ≥ 5% with SF3B1 mutation for MDS-RS).
-
HK relevance: Think of INH (TB treatment), alcohol, and MDS-RS in elderly.
High Yield Summary — Differential Diagnosis
When you see microcytic anemia with raised iron studies → think sideroblastic anemia (not IDA!).
When you see macrocytic anemia in elderly → MDS-RS is a key differential alongside B12/folate deficiency and other MDS subtypes.
The gold standard to distinguish SA from other anemias is bone marrow Prussian blue stain showing ring sideroblasts.
Once ring sideroblasts are confirmed, differentiate by:
High Yield Summary — Diagnostic Approach
-
Gold standard for SA diagnosis: Bone marrow aspirate with Perl's Prussian Blue stain showing ≥ 15% ring sideroblasts (or ≥ 5% with SF3B1 mutation for MDS-RS) [5][9]
-
Key iron studies pattern: ↑ serum iron, ↑ ferritin, N/↓ TIBC, ↑ TSAT — opposite to IDA
-
PBS clues before BM: Dimorphic red cells + Pappenheimer bodies + high RDW → strongly suspect SA
-
Top differential for SA: always think MDS — especially in elderly patients [5]
-
SF3B1 mutation: Present in ~80-90% of MDS-RS; favorable prognosis; lowers RS threshold to 5%
-
Reversible causes must be excluded FIRST: Check B6, B12/folate, copper, lead level, drug history before labeling as MDS
-
Iron overload monitoring: MRI T2 of liver and heart* is the standard — replaces liver biopsy and ferritin [14]
-
BM for aplastic anemia shows hypocellular marrow with no dysplasia; BM for MDS-RS shows hypercellular marrow with dysplasia and ring sideroblasts — completely opposite pictures despite both causing cytopenia [2][9]
High Yield Summary — Management
Management of SA follows the underlying cause:
-
Reversible SA: Remove offending agent (INH, alcohol, lead, zinc) + supplement B6/copper/folate. Ring sideroblasts resolve rapidly.
-
Hereditary SA: Trial of high-dose pyridoxine (50-200 mg/day × 3 months). If responsive → lifelong B6. If non-responsive → transfusion + iron chelation ± HSCT.
-
MDS-RS (most common acquired): Risk-stratify with IPSS-R/IPSS-M.
- Lower risk: ESA (if EPO ≤ 500) → luspatercept (MDS-RS specific) → transfusion + chelation
- Higher risk: Hypomethylating agents (azacitidine) → allogeneic HSCT
-
Iron overload management: Critical in all chronic SA.
- Three chelators: DFO (SC/IV), deferiprone (PO), deferasirox (PO)
- Monitor with MRI T2 liver and heart*
- Start when ferritin > 1000 or LIC > 7 mg/g
-
NEVER give iron supplements to SA patients — they are already iron-overloaded.
-
Folate supplementation recommended for all chronic SA (compensates for increased folate consumption from ineffective erythropoiesis).
High Yield Summary — Complications
-
Iron overload is the #1 cause of morbidity and mortality in chronic/transfusion-dependent SA. Cardiac iron overload is the leading cause of death.
-
Each unit of blood = ~200 mg iron; only 1 mg/day excreted. The body has no active iron excretion mechanism — chelation is the only medical way to remove excess iron.
-
Iron damages organs via the Fenton/Haber-Weiss reaction (iron catalyzes H₂O₂ → ROS → oxidative damage).
-
Organ damage pattern: Heart (cardiomyopathy) > Liver (cirrhosis/HCC) > Endocrine (DM, hypogonadism, hypothyroidism) > Joints (arthropathy) — pituitary is often the first endocrine organ affected.
-
MDS-RS with SF3B1 mutation has low AML transformation risk (~5-10%) — but adverse co-mutations (TP53, ASXL1) worsen prognosis.
-
Monitor with: MRI T2 heart and liver annually; ferritin q3 months; endocrine workup annually; US HBP q6 months (if cirrhosis for HCC screening).*
-
Always supplement folate in chronic SA (increased consumption from ineffective erythropoiesis).
-
Treatment complications: DFO → ototoxicity; Deferiprone → agranulocytosis (weekly ANC!); Deferasirox → hepatorenal toxicity.
Thalassemia
Thalassemia is a group of inherited hemoglobin disorders characterized by reduced or absent synthesis of one or more globin chains, leading to ineffective erythropoiesis and microcytic hypochromic anemia.
Anaemia Of Chronic Disease
Anaemia of chronic disease is a hypoproliferative anaemia arising in the setting of chronic infection, inflammation, or malignancy, mediated largely by hepcidin-induced iron sequestration and impaired erythropoiesis.